PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3191165-11 1988 The enhancing effect of dexamethasone was also observed when cultures were performed in the absence of insulin and/or in serum-free media. Dexamethasone 24-37 insulin Homo sapiens 103-110 2651092-0 1989 Dexamethasone regulates the glucose transport system in primary cultured adipocytes: different mechanisms of insulin resistance after acute and chronic exposure. Dexamethasone 0-13 insulin Homo sapiens 109-116 2651092-2 1989 Acutely, 20 nM dexamethasone led to a 65% decrease in basal and a 31% decrement in maximally insulin-stimulated glucose transport (ED50 = 3-4 nM; t1/2 = 50 min). Dexamethasone 15-28 insulin Homo sapiens 93-100 2651092-3 1989 These effects were maximal by 90-120 min, and a plateau was maintained over an additional 1-1.5 h. Chronic dexamethasone exposure (24 h) led to a more profound decrease in basal (77%; ED50 = 0.4 nM) and maximally stimulated (55%; ED50 = 1.0 nM) rates of glucose transport and shifted the transport: insulin dose-response curve to the right by increasing the half-maximally effective insulin concentration from 0.2 to 0.4 ng/ml. Dexamethasone 107-120 insulin Homo sapiens 299-306 2651092-3 1989 These effects were maximal by 90-120 min, and a plateau was maintained over an additional 1-1.5 h. Chronic dexamethasone exposure (24 h) led to a more profound decrease in basal (77%; ED50 = 0.4 nM) and maximally stimulated (55%; ED50 = 1.0 nM) rates of glucose transport and shifted the transport: insulin dose-response curve to the right by increasing the half-maximally effective insulin concentration from 0.2 to 0.4 ng/ml. Dexamethasone 107-120 insulin Homo sapiens 383-390 2651092-4 1989 Dexamethasone did not affect cell surface insulin binding over 24 h. Both the short and long term effects of dexamethasone were partially blocked by the combined presence of insulin during preincubation and were not modulated by glucose. Dexamethasone 109-122 insulin Homo sapiens 174-181 2651092-6 1989 After 2 h, dexamethasone (30 nM) decreased the number of glucose transporters in plasma membranes by 30% in basal cells and by 41% in maximally insulin-stimulated cells, while increasing the number of low density microsomal transporters by 22-23% (P = NS). Dexamethasone 11-24 insulin Homo sapiens 144-151 2651092-8 1989 Chronic dexamethasone exposure (24 h) decreased plasma membrane and low density microsomal transporters by 30-50% in both basal and insulin-stimulated cells and depleted transporters by 43% in a total cellular membrane fraction. Dexamethasone 8-21 insulin Homo sapiens 132-139 2651092-9 1989 In conclusion, 1) dexamethasone induces progressive insulin resistance by sequentially regulating multiple aspects of the insulin-responsive glucose transport system. Dexamethasone 18-31 insulin Homo sapiens 52-59 2651092-10 1989 At early times (2 h) dexamethasone impairs insulin"s ability to translocate intracellular glucose transporters to the cell surface and with more chronic exposure (24 h), depletes the total number of cellular transporters. Dexamethasone 21-34 insulin Homo sapiens 43-50 2651092-12 1989 3) Insulin can heterologously inhibit dexamethasone"s effects on glucose transport at both early and late phases of desensitization. Dexamethasone 38-51 insulin Homo sapiens 3-10 2677680-0 1989 Expression of a glucose transporter gene cloned from brain in cellular models of insulin resistance: dexamethasone decreases transporter mRNA in primary cultured adipocytes. Dexamethasone 101-114 insulin Homo sapiens 81-88 2677680-4 1989 Dexamethasone"s effects to decrease transport rates, transporter protein, and mRNA were inhibited by coincubation with insulin. Dexamethasone 0-13 insulin Homo sapiens 119-126 2677680-9 1989 3) Insulin heterologously inhibits regulation of the glucose transport system by dexamethasone. Dexamethasone 81-94 insulin Homo sapiens 3-10 2677680-10 1989 4) Dexamethasone-mediated insulin resistance is due in part to regulation of a glucose transporter species encoded by cDNA cloned from brain. Dexamethasone 3-16 insulin Homo sapiens 26-33 2661519-7 1989 Dexamethasone also potentiated IGF-I, insulin, and epidermal growth factor stimulation of fibroblast replication depending on the earlier subcultivation conditions. Dexamethasone 0-13 insulin Homo sapiens 38-45 3141685-10 1988 Recently, we have shown that insulin and tri-iodothyronine (T3) increase the specific binding of LDL to cultured hepatocytes whereas dexamethasone (a synthetic glucocorticoid) has the opposite effect. Dexamethasone 133-146 insulin Homo sapiens 29-36 3277620-14 1988 In young cultures (up to 24 h old) dexamethasone protected against inhibition by insulin, but was ineffective in older cultures. Dexamethasone 35-48 insulin Homo sapiens 81-88 3541907-8 1986 The insulin-dependent increase in cell-surface enzyme was potentiated somewhat in the presence of dexamethasone, which was not shown to exert any independent effect. Dexamethasone 98-111 insulin Homo sapiens 4-11 2826429-5 1987 However, addition of insulin for 30 min to cells that had been treated for 4 h with dexamethasone completely reversed the dexamethasone-induced decrease in glucose transport and also reversed the dexamethasone-induced changes in glucose transporter polypeptide content of the plasma membrane and P2 fractions. Dexamethasone 84-97 insulin Homo sapiens 21-28 2826429-5 1987 However, addition of insulin for 30 min to cells that had been treated for 4 h with dexamethasone completely reversed the dexamethasone-induced decrease in glucose transport and also reversed the dexamethasone-induced changes in glucose transporter polypeptide content of the plasma membrane and P2 fractions. Dexamethasone 122-135 insulin Homo sapiens 21-28 2826429-5 1987 However, addition of insulin for 30 min to cells that had been treated for 4 h with dexamethasone completely reversed the dexamethasone-induced decrease in glucose transport and also reversed the dexamethasone-induced changes in glucose transporter polypeptide content of the plasma membrane and P2 fractions. Dexamethasone 122-135 insulin Homo sapiens 21-28 2826429-6 1987 From these observations we conclude that dexamethasone decreases glucose transport by causing translocation of glucose transporters from the plasma membrane to an internal location and that insulin reverses the dexamethasone effect by reversing the translocation. Dexamethasone 211-224 insulin Homo sapiens 190-197 3307259-2 1987 The authors feel that this therapeutic regimen could be useful when conventional treatments (the injection of regular purified insulin or dexamethasone-insulin mixtures in the area of the lesion) have failed to obtain good results. Dexamethasone 138-151 insulin Homo sapiens 152-159 3780558-5 1987 The increase produced by hydrogen peroxide, as well as insulin, was inhibited by previous incubation of the cells with dexamethasone. Dexamethasone 119-132 insulin Homo sapiens 55-62 3322910-5 1987 Dexamethasone treatment (6 mg/day for 3 days) raised the proinsulin to immunoreactive insulin ratio in control subjects from 13 +/- 2 to 21 +/- 2% (p less than 0.0001) and in diabetic patients from 29 +/- 5 to 52 +/- 7% (p less than 0.001). Dexamethasone 0-13 insulin Homo sapiens 57-67 3322910-5 1987 Dexamethasone treatment (6 mg/day for 3 days) raised the proinsulin to immunoreactive insulin ratio in control subjects from 13 +/- 2 to 21 +/- 2% (p less than 0.0001) and in diabetic patients from 29 +/- 5 to 52 +/- 7% (p less than 0.001). Dexamethasone 0-13 insulin Homo sapiens 60-67 3322910-6 1987 Dexamethasone also raised the ratio of the acute proinsulin response to the acute immunoreactive insulin response in control subjects from 2 +/- 0.5 to 5 +/- 2% (p = 0.01) and in diabetic patients from 8 +/- 2 to 14 +/- 4% (p = NS), suggesting that the dexamethasone-induced increment in the basal ratio of proinsulin to immunoreactive insulin was also due to increased secretion. Dexamethasone 0-13 insulin Homo sapiens 49-59 3322910-6 1987 Dexamethasone also raised the ratio of the acute proinsulin response to the acute immunoreactive insulin response in control subjects from 2 +/- 0.5 to 5 +/- 2% (p = 0.01) and in diabetic patients from 8 +/- 2 to 14 +/- 4% (p = NS), suggesting that the dexamethasone-induced increment in the basal ratio of proinsulin to immunoreactive insulin was also due to increased secretion. Dexamethasone 0-13 insulin Homo sapiens 52-59 3322910-6 1987 Dexamethasone also raised the ratio of the acute proinsulin response to the acute immunoreactive insulin response in control subjects from 2 +/- 0.5 to 5 +/- 2% (p = 0.01) and in diabetic patients from 8 +/- 2 to 14 +/- 4% (p = NS), suggesting that the dexamethasone-induced increment in the basal ratio of proinsulin to immunoreactive insulin was also due to increased secretion. Dexamethasone 0-13 insulin Homo sapiens 307-317 3322910-6 1987 Dexamethasone also raised the ratio of the acute proinsulin response to the acute immunoreactive insulin response in control subjects from 2 +/- 0.5 to 5 +/- 2% (p = 0.01) and in diabetic patients from 8 +/- 2 to 14 +/- 4% (p = NS), suggesting that the dexamethasone-induced increment in the basal ratio of proinsulin to immunoreactive insulin was also due to increased secretion. Dexamethasone 0-13 insulin Homo sapiens 97-104 3310195-2 1987 Dexamethasone caused impaired glucose tolerance, which was associated with an exaggerated insulin (0.61 +/- 0.05 vs. 0.38 +/- 0.05 nmol/l; p less than 0.001). Dexamethasone 0-13 insulin Homo sapiens 90-97 3310195-6 1987 The mechanism(s) for the decreased GIP response after dexamethasone could involve (1) a direct inhibitory effect on GIP secretion by dexamethasone, and/or (2) a negative feedback of elevated glucose and insulin levels on GIP secretion. Dexamethasone 54-67 insulin Homo sapiens 203-210 3498926-0 1987 Impaired synergism between somatomedin C/insulin-like growth factor I and dexamethasone in the growth of fibroblasts from a patient with insulin resistance. Dexamethasone 74-87 insulin Homo sapiens 137-144 3498926-8 1987 Furthermore, the stimulation of cell replication by SM-C/IGF-I and insulin was potentiated by dexamethasone in control but not DF cultures. Dexamethasone 94-107 insulin Homo sapiens 67-74 3294879-5 1987 In normal subjects plasma CRH levels increased after insulin-induced hypoglycemia; this response was abolished by the prior administration of dexamethasone. Dexamethasone 142-155 insulin Homo sapiens 53-60 3294879-12 1987 These findings suggest that immunoreactive CRH is present in peripheral plasma; the increase in plasma immunoreactive CRH after insulin-induced hypoglycemia may reflect stimulation of hypothalamic CRH release; the increase in plasma immunoreactive CRH after glucose administration may reflect extrahypothalamic CRH release; and the lack of diurnal variation in plasma immunoreactive CRH together with the lack of suppression of CRH by dexamethasone suggest that basal plasma CRH is of extrahypothalamic origin. Dexamethasone 435-448 insulin Homo sapiens 128-135 2581555-1 1985 Chronic exposure of 3T3-L1 pre-adipocytes to dexamethasone plus 3-isobutyl-1-methylxanthine (IBMX) with or without insulin caused a significant increase in the specific activity of "total" pyruvate dehydrogenase complex (PDC) and in the percentage of the "active" form of the complex compared with cells exposed to a chronic insulin treatment or an acute treatment (2 days) with dexamethasone plus IBMX. Dexamethasone 379-392 insulin Homo sapiens 115-122 3522357-5 1986 Dexamethasone amplification of the insulin-stimulated DNA synthetic response over a range of insulin concentrations (i.e. 1.6-66.6 nM) expressed no differences between the two donor groups. Dexamethasone 0-13 insulin Homo sapiens 35-42 2581555-1 1985 Chronic exposure of 3T3-L1 pre-adipocytes to dexamethasone plus 3-isobutyl-1-methylxanthine (IBMX) with or without insulin caused a significant increase in the specific activity of "total" pyruvate dehydrogenase complex (PDC) and in the percentage of the "active" form of the complex compared with cells exposed to a chronic insulin treatment or an acute treatment (2 days) with dexamethasone plus IBMX. Dexamethasone 45-58 insulin Homo sapiens 325-332 2415243-7 1985 On the other hand, when dexamethasone and insulin were added simultaneously, the dexamethasone-mediated stimulation of AFP secretions was diminished. Dexamethasone 81-94 insulin Homo sapiens 42-49 3894022-8 1985 Physiological concentrations of insulin strongly suppressed the stimulatory effect of dexamethasone on the enzyme synthesis but could not completely counteract the effect of dexamethasone. Dexamethasone 86-99 insulin Homo sapiens 32-39 2984220-6 1985 All of the insulin effects are antagonized by dexamethasone. Dexamethasone 46-59 insulin Homo sapiens 11-18 3880762-3 1985 Furthermore, 10(-7)M dexamethasone dramatically potentiated SM-C stimulation (70-fold) and insulin stimulation (28-fold) of 3H-thymidine incorporation. Dexamethasone 21-34 insulin Homo sapiens 91-98 3881461-0 1985 Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium. Dexamethasone 0-13 insulin Homo sapiens 74-81 3881461-5 1985 Dexamethasone had a similar effect in the presence of insulin. Dexamethasone 0-13 insulin Homo sapiens 54-61 3881461-7 1985 These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF. Dexamethasone 32-45 insulin Homo sapiens 223-230 3880762-4 1985 With dexamethasone and 0.25% HHS, significant stimulation of DNA synthesis was seen at 2.5 ng/ml for both SM-C and insulin. Dexamethasone 5-18 insulin Homo sapiens 115-122 3880762-11 1985 Both SM-C and insulin are also capable of synergism with low concentrations of serum and dexamethasone in the stimulation of DNA synthesis and cell replication. Dexamethasone 89-102 insulin Homo sapiens 14-21 6323329-1 1984 A new property, i.e. acquisition of insulin (insulin + dexamethasone)-mediated enhancement of anchorage independence by heterologous MuMTV-infected cells, is described. Dexamethasone 55-68 insulin Homo sapiens 36-43 6397420-4 1984 The continuous presence of dexamethasone amplified the insulin-induced glycogen synthesis. Dexamethasone 27-40 insulin Homo sapiens 55-62 6388353-0 1984 Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Dexamethasone 0-13 insulin Homo sapiens 22-29 6388353-3 1984 During Dex there were elevations above control levels of basal glucose (104 +/- 2 vs. 94 +/- 3 mg/dl) and insulin (21 +/- 3 vs. 13 +/- 2 microU/ml, both P less than 0.03). Dexamethasone 7-10 insulin Homo sapiens 106-113 6388353-6 1984 Similarly, matched increments in glucose level produced greater increments in prestimulus insulin level during Dex (P less than 0.03). Dexamethasone 111-114 insulin Homo sapiens 90-97 6388353-8 1984 Because the direct effect of glucocorticoids on B cell function has been reported to be inhibitory, the observed stimulation is likely to be a result of the insulin resistance caused by Dex. Dexamethasone 186-189 insulin Homo sapiens 157-164 3894803-8 1985 In vitro studies with IM-9, NALM-1 and NALM-16 cell lines showed that changes in insulin binding caused by dexamethasone treatment were not correlated with hormone-induced cell death. Dexamethasone 107-120 insulin Homo sapiens 81-88 6323329-1 1984 A new property, i.e. acquisition of insulin (insulin + dexamethasone)-mediated enhancement of anchorage independence by heterologous MuMTV-infected cells, is described. Dexamethasone 55-68 insulin Homo sapiens 45-52 6373243-0 1983 Up-regulation of insulin receptors with dexamethasone in cultured human urinary bladder carcinoma cells. Dexamethasone 40-53 insulin Homo sapiens 17-24 6397777-0 1984 Effects of lithium, nortriptyline and dexamethasone on insulin sensitivity. Dexamethasone 38-51 insulin Homo sapiens 55-62 6397777-4 1984 However, after three weeks of lithium treatment the dexamethasone premedication resulted in slight flattening of glucose response to insulin in the same persons. Dexamethasone 52-65 insulin Homo sapiens 133-140 6373243-1 1983 Cultured human urinary bladder carcinoma cells ( JTC -32) were used to investigate the regulation of insulin receptors by dexamethasone. Dexamethasone 122-135 insulin Homo sapiens 101-108 6373243-2 1983 When the cells were preincubated with dexamethasone at 37 degrees C, insulin binding sites increased up to 24 h. A large increase in insulin binding sites took place for 14 h of preincubation with dexamethasone. Dexamethasone 38-51 insulin Homo sapiens 69-76 6373243-2 1983 When the cells were preincubated with dexamethasone at 37 degrees C, insulin binding sites increased up to 24 h. A large increase in insulin binding sites took place for 14 h of preincubation with dexamethasone. Dexamethasone 38-51 insulin Homo sapiens 133-140 6373243-2 1983 When the cells were preincubated with dexamethasone at 37 degrees C, insulin binding sites increased up to 24 h. A large increase in insulin binding sites took place for 14 h of preincubation with dexamethasone. Dexamethasone 197-210 insulin Homo sapiens 69-76 6373243-2 1983 When the cells were preincubated with dexamethasone at 37 degrees C, insulin binding sites increased up to 24 h. A large increase in insulin binding sites took place for 14 h of preincubation with dexamethasone. Dexamethasone 197-210 insulin Homo sapiens 133-140 6373243-4 1983 Scatchard plots showed that dexamethasone increased the number of high affinity insulin binding sites (2.8 fold) without any change in the apparent equilibrium constant in JTC -32 cells. Dexamethasone 28-41 insulin Homo sapiens 80-87 6357090-5 1983 Further, hydrocortisone and dexamethasone (both at 5 X 10(-6) M) exhibited potentiating effects on insulin-stimulated sugar transport. Dexamethasone 28-41 insulin Homo sapiens 99-106 6357090-4 1983 In dexamethasone-treated cells, concentrations of insulin as low as 250 microU/ml (10 ng/ml) were effective in stimulating DNA synthesis. Dexamethasone 3-16 insulin Homo sapiens 50-57 6310564-7 1983 The expression of preproinsulin-beta-galactosidase activity was measured in the presence of high glucose, insulin, dexamethasone, or epidermal growth factor but no regulatory changes were observed. Dexamethasone 115-128 insulin Homo sapiens 18-31 6310564-7 1983 The expression of preproinsulin-beta-galactosidase activity was measured in the presence of high glucose, insulin, dexamethasone, or epidermal growth factor but no regulatory changes were observed. Dexamethasone 115-128 insulin Homo sapiens 24-31 6190811-10 1983 Incubation of adipocytes for 48 h with 1 microM dexamethasone prevented insulin-induced activation of the particulate phosphodiesterase and did not alter basal activity. Dexamethasone 48-61 insulin Homo sapiens 72-79 6190811-11 1983 After incubation for 72 h with 0.1 microM dexamethasone, insulin and epinephrine activation were abolished. Dexamethasone 42-55 insulin Homo sapiens 57-64 6190811-12 1983 These effects of dexamethasone on hormonal regulation of particulate phosphodiesterase activity could account for some of the so-called permissive effects of glucocorticoids on cAMP-mediated processes as well as the "anti-insulin" effects of glucocorticoids. Dexamethasone 17-30 insulin Homo sapiens 222-229 6341122-5 1983 From 2400-0300 to 0600-0900 h, mean insulin infusion rates required to maintain blood glucose values between 109 and 120 mg/dl increased by 0.21 +/- 0.05 mU/kg/min during the SAL infusion, and 0.16 +/- 0.04 mU/kg/min during the DEX infusion, when plasma cortisols were suppressed to less than or equal to 2 micrograms/dl. Dexamethasone 228-231 insulin Homo sapiens 36-43 6337579-4 1983 There was also a trend toward a decrease in insulin sensitivity in patients who had been nonsuppressors to dexamethasone when depressed. Dexamethasone 107-120 insulin Homo sapiens 44-51 6397777-5 1984 Nortriptyline administered for three weeks to healthy volunteers, pretreated with dexamethasone, increased insulin sensitivity. Dexamethasone 82-95 insulin Homo sapiens 107-114 6347191-3 1983 In contrast, primary cultures of hepatocytes incubated with dexamethasone plus insulin are hyper-responsive to the ability of insulin to stimulate lipogenesis chronically. Dexamethasone 60-73 insulin Homo sapiens 126-133 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 12-25 insulin Homo sapiens 101-108 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 12-25 insulin Homo sapiens 101-108 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 12-25 insulin Homo sapiens 101-108 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 12-25 insulin Homo sapiens 101-108 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 171-184 insulin Homo sapiens 31-38 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 171-184 insulin Homo sapiens 101-108 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 171-184 insulin Homo sapiens 101-108 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 171-184 insulin Homo sapiens 101-108 6347191-5 1983 Exposure to dexamethasone plus insulin for more than 4 h is required for the two hormones to enhance insulin action either by overcoming the insulin resistance induced by dexamethasone alone or by stimulating insulin action induced by insulin alone. Dexamethasone 171-184 insulin Homo sapiens 101-108 6347191-6 1983 Despite the marked potentiation of insulin action, hepatocytes exposed to dexamethasone plus insulin are less sensitive to insulin, as demonstrated by a shift to the right in the dose-response curve for insulin-stimulated lipogenesis. Dexamethasone 74-87 insulin Homo sapiens 35-42 6749880-0 1982 Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes. Dexamethasone 96-109 insulin Homo sapiens 113-120 6749880-3 1982 Although both hydrocortisone and dexamethasone caused significant reduction in insulin binding compared to that during the pretreatment period (11.0 +/- 0.7 vs. 9.0 +/- 0.5% (P less than 0.01) and 11.8 +/- 0.7 vs. 9.0 +/- 0.5% (P less than 0.05), respectively), prednisone ingestion did not significantly alter insulin binding (10.6 +/- 0.6 before vs. 9.4 +/- 0.5% after). Dexamethasone 33-46 insulin Homo sapiens 79-86 6749880-3 1982 Although both hydrocortisone and dexamethasone caused significant reduction in insulin binding compared to that during the pretreatment period (11.0 +/- 0.7 vs. 9.0 +/- 0.5% (P less than 0.01) and 11.8 +/- 0.7 vs. 9.0 +/- 0.5% (P less than 0.05), respectively), prednisone ingestion did not significantly alter insulin binding (10.6 +/- 0.6 before vs. 9.4 +/- 0.5% after). Dexamethasone 33-46 insulin Homo sapiens 311-318 6749880-6 1982 We conclude that although hydrocortisone, dexamethasone, and prednisone all cause deterioration of glucose tolerance and decreased insulin sensitivity, only hydrocortisone and dexamethasone exhibit significant decreases in insulin binding to erythrocytes. Dexamethasone 42-55 insulin Homo sapiens 131-138 7028594-1 1981 The effect of oral administration of dexamethasone or cortisone on circulating red blood cell (RBC) insulin receptors was evaluated in normal males before treatment and 24 h (day 1), 48 h (day 2) and 72 h (day 3) after the commencement of steroid administration. Dexamethasone 37-50 insulin Homo sapiens 100-107 7042322-0 1982 Influence of dexamethasone on insulin action: inhibition of basal and insulin-stimulated hexose transport is dependent on length of exposure in vitro. Dexamethasone 13-26 insulin Homo sapiens 30-37 7042322-0 1982 Influence of dexamethasone on insulin action: inhibition of basal and insulin-stimulated hexose transport is dependent on length of exposure in vitro. Dexamethasone 13-26 insulin Homo sapiens 70-77 7002662-0 1980 Decreased insulin binding of human erythrocytes after dexamethasone or prednisone ingestion. Dexamethasone 54-67 insulin Homo sapiens 10-17 7002662-1 1980 We have investigated changes in insulin binding in erythrocytes in response to overnight ingestion of 1 mg dexamethasone or 10 mg of prednisone in two groups of eight lean, healthy subjects. Dexamethasone 107-120 insulin Homo sapiens 32-39 7002662-2 1980 Dexamethasone administration reduced insulin binding from 9.6 to 6.8% (P < 0.001) with concomitant increase in basal plasma insulin from 10.5 to 14.1 microU/ml (P < 0.05). Dexamethasone 0-13 insulin Homo sapiens 37-44 7002662-2 1980 Dexamethasone administration reduced insulin binding from 9.6 to 6.8% (P < 0.001) with concomitant increase in basal plasma insulin from 10.5 to 14.1 microU/ml (P < 0.05). Dexamethasone 0-13 insulin Homo sapiens 127-134 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Dexamethasone 42-55 insulin Homo sapiens 16-23 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Dexamethasone 42-55 insulin Homo sapiens 129-136 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Dexamethasone 42-55 insulin Homo sapiens 129-136 7002662-5 1980 The earliest decrease in insulin binding was noted within 2 h after ingestion of 1 mg of dexamethasone. Dexamethasone 89-102 insulin Homo sapiens 25-32 1159053-0 1975 Altered hypothalamic-pituitary-adrenal responsiveness to dexamethasone-insulin tolerance test in active acromegaly. Dexamethasone 57-70 insulin Homo sapiens 71-78 445441-3 1979 Pharmacological concentrations of dexamethasone (10 nM) reduced cell number below that found in controls and nearly abolished the effect of insulin after several days in culture. Dexamethasone 34-47 insulin Homo sapiens 140-147 849810-3 1977 With the continued use of dexamethasone-containing insulin, they remained mostly free of atrophic areas during the follow-up period of over two years. Dexamethasone 26-39 insulin Homo sapiens 51-58 65340-7 1977 Prolactin, and more efficiently the prolactin-insulin combination, enhanced the MMTV production stumulated with dexamethasone. Dexamethasone 112-125 insulin Homo sapiens 46-53 788430-0 1976 The insulin tolerance test after pre-treatment with dexamethasone. Dexamethasone 52-65 insulin Homo sapiens 4-11 788430-6 1976 After pre-treatment with dexamethasone the subjects experienced less discomfort and a shorter duration of sweating than in the control insulin tolerance test. Dexamethasone 25-38 insulin Homo sapiens 135-142 6997328-0 1980 Effect of dexamethasone and cortisone on insulin receptors in normal human male. Dexamethasone 10-23 insulin Homo sapiens 41-48 6997328-6 1980 Furthermore, since dexamethasone and cortisone affect plasma insulin levels in the same fashion as previously reported with prednisone, it is suggested that the variation in insulin binding observed after glucocorticoid treatment is not due to variations in insulinemia. Dexamethasone 19-32 insulin Homo sapiens 61-68 445441-6 1979 Net thymidine uptake into the trichloroacetic acid-soluble fraction of the cell was stimulated by insulin and inhibited by dexamethasone also inhibited thymidine kinase activity multiple potential sites of glucocorticoid action that directly oppose the effects of insulin. Dexamethasone 123-136 insulin Homo sapiens 264-271 580533-0 1978 Hypothalmic-pituitary adrenal responsiveness to dexamethasone-insulin tolerance test in acromegalic patients before and during treatment with bromocriptine. Dexamethasone 48-61 insulin Homo sapiens 62-69 24459-2 1978 Similar therapy in a chemical diabetic patient caused diabetic ketoacidosis, while treatment of an insulin dependent diabetic with dexamethasone alone resulted in a major increase in her insulin requirements. Dexamethasone 131-144 insulin Homo sapiens 99-106 946314-2 1976 Subsequent systemic treatment with a dexamethasone (0.08 mg/day) insulin mixture injected subcutaneously into the depressed areas resulted in an impressive return of subcutaneous tissue after eight months of continuous therapy. Dexamethasone 37-50 insulin Homo sapiens 65-72 4630099-0 1972 Antagonism of insulin action on glucose metabolism in white fat cells by dexamethasone. Dexamethasone 73-86 insulin Homo sapiens 14-21 1117842-0 1975 The effects of acute and chronic dexamethasone administration on insulin binding to isolated rat hepatocytes and adipocytes. Dexamethasone 33-46 insulin Homo sapiens 65-72 32210313-7 2020 We found that like dexamethasone, budesonide inhibits adipogenesis induced by insulin in sub-confluent FAPs. Dexamethasone 19-32 insulin Homo sapiens 78-85 31917277-5 2020 AIM OF THE STUDY: The aim of this study was to identify the main active components in LSF that can inhibit the hyperphosphorylation of Tau through improving insulin resistance (IR) in dexamethasone (DXM)-induced HepG2 and HT22 cells. Dexamethasone 184-197 insulin Homo sapiens 157-164 31917277-5 2020 AIM OF THE STUDY: The aim of this study was to identify the main active components in LSF that can inhibit the hyperphosphorylation of Tau through improving insulin resistance (IR) in dexamethasone (DXM)-induced HepG2 and HT22 cells. Dexamethasone 199-202 insulin Homo sapiens 157-164 31761675-3 2020 The goal of this study is to determine if administration of preoperative dexamethasone to diabetic patients is significantly associated with hyperglycemia and increased insulin requirements in the immediate postoperative period after TJA and to identify risk factors for postoperative hyperglycemia immediately after TJA. Dexamethasone 73-86 insulin Homo sapiens 169-176 31761675-10 2020 Dexamethasone administration was associated with increased aspart insulin requirements on postoperative day 0 (P = .04). Dexamethasone 0-13 insulin Homo sapiens 66-73 31761675-12 2020 CONCLUSION: Preoperative dexamethasone administration to diabetic patients was associated with an initial increase in blood glucose and increased insulin requirement on postoperative day 0. Dexamethasone 25-38 insulin Homo sapiens 146-153 32029226-16 2020 Increasing GAS5 levels using GAS5 HREM alleviated the inhibitory effects of dexamethasone on insulin secretion. Dexamethasone 76-89 insulin Homo sapiens 93-100 31729529-5 2019 RESULTS: CAA improved dexamethasone-induced reduction of glucose consumption in HepG2 cells, inhibited hepatocyte production of IL-6 and TGF-beta, increased the expression of IL-17RC cell, and increased cellular apoptosis in insulin-resistant HepG2 cells. Dexamethasone 22-35 insulin Homo sapiens 225-232 30910285-0 2019 Corrigendum to "Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients" [Int. Dexamethasone 16-29 insulin Homo sapiens 126-133 31246234-12 2019 In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. Dexamethasone 7-20 insulin Homo sapiens 59-66 31246234-12 2019 In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. Dexamethasone 7-20 insulin Homo sapiens 103-110 30910285-0 2019 Corrigendum to "Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients" [Int. Dexamethasone 16-29 insulin Homo sapiens 152-159 31384718-15 2019 Conclusions: Long-term and low-dose DEX therapy did not lead to increases in obesity or metabolic syndrome, although it was associated with an increased WtHR and greater homeostatic model assessment for insulin resistance observed with chronic use of GCs. Dexamethasone 36-39 insulin Homo sapiens 203-210 30953748-9 2019 Dexamethasone can regulate LCN2 expression via inhibition of ERalpha and stimulation of ERbeta and may contribute to the development of glucocorticoid-induced insulin resistance in human AT. Dexamethasone 0-13 insulin Homo sapiens 159-166 30704815-0 2019 Successful management of type IV hypersensitivity reactions to human insulin analogue with injecting mixtures of biphasic insulin aspart and dexamethasone. Dexamethasone 141-154 insulin Homo sapiens 69-76 30568127-5 2019 GLP-1 RAs can be switched to insulin in order to eliminate the slow absorption effect of dexamethasone by GLP-1 RAs if a DST is planned in diabetic patients receiving GLP-1 RAs. Dexamethasone 89-102 insulin Homo sapiens 29-36 29864432-10 2018 Patients receiving dexamethasone required significantly more insulin compared with patients in the control group (P < .001). Dexamethasone 19-32 insulin Homo sapiens 61-68 29513794-6 2018 Dexamethasone disrupted the insulin-reduced Enpp1 expression in primary hepatocytes. Dexamethasone 0-13 insulin Homo sapiens 28-35 29409992-7 2018 Pathway analysis showed that the fatty acid biosynthesis, insulin resistance, PPAR signaling pathway, regulation of lipolysis in adipocytes, carbohydrate digestion and absorption, steroid hormone biosynthesis signaling pathways had a close relationship with dexamethasone induced steatosis. Dexamethasone 258-271 insulin Homo sapiens 58-65 29169823-6 2018 The dexamethasone group had significantly lower preoperative blood glucose (135.5 mmol/L) compared to the control group (144.4 mmol/L) (p = 0.04) and significantly lower proportion of patients who had received insulin during surgery (14.9%) compared to the control group (23.4%) (p = 0.04). Dexamethasone 4-17 insulin Homo sapiens 210-217 26879182-0 2016 15 Hz electroacupuncture at ST36 improves insulin sensitivity and reduces free fatty acid levels in rats with chronic dexamethasone-induced insulin resistance. Dexamethasone 118-131 insulin Homo sapiens 140-147 29369181-1 2018 Dexamethasone (DEX) could induce low birth weight of infant, and low birth weight has close associations with glucocorticoid levels, insulin resistance, hypertension, and metabolic syndrome in adulthood. Dexamethasone 0-13 insulin Homo sapiens 133-140 29369181-1 2018 Dexamethasone (DEX) could induce low birth weight of infant, and low birth weight has close associations with glucocorticoid levels, insulin resistance, hypertension, and metabolic syndrome in adulthood. Dexamethasone 15-18 insulin Homo sapiens 133-140 27540825-5 2018 Following intravitreal dexamethasone implant, her oral steroid use was tapered with subsequent improvement in her diabetes and eventual cessation of insulin. Dexamethasone 23-36 insulin Homo sapiens 149-156 27363591-16 2017 Plasma adiponectin, and serum basal (insulin) and (insulin) post-dexamethasone levels were significantly (P <= 0.05) associated with laminitis occurrence cumulatively after 1, 2 and 3 years. Dexamethasone 65-78 insulin Homo sapiens 51-58 27363591-19 2017 CONCLUSIONS: Risk factors for future laminitis prior to disease occurrence include low plasma adiponectin and high serum basal insulin or insulin post-dexamethasone concentrations. Dexamethasone 151-164 insulin Homo sapiens 138-145 28397446-3 2017 The N363S polymorphism has been associated with increased sensitivity to glucocorticoides, increased insulin response to dexamethasone and increased plasma glucose level. Dexamethasone 121-134 insulin Homo sapiens 101-108 27177506-1 2016 AIMS/INTRODUCTION: Our previous study found that dexamethasone-induced insulin resistance (IR) was involved in 5-hydroxytryptamine (5-HT) synthesis and 5-hydroxytryptamine 2 receptor (5-HT2 R) in the periphery. Dexamethasone 49-62 insulin Homo sapiens 71-78 26879182-2 2016 METHODS: An SIIR rat model was created using daily intraperitoneal injections of clinically relevant doses of dexamethasone (1 mg/kg) for 5 days to induce chronic insulin resistance. Dexamethasone 110-123 insulin Homo sapiens 163-170 26879182-11 2016 Further clinical studies are needed to determine whether EA is an effective alternative treatment for the reduction of insulin resistance in patients requiring chronic use of dexamethasone. Dexamethasone 175-188 insulin Homo sapiens 119-126 26077651-0 2015 A Triterpenoid Inhibited Hormone-Induced Adipocyte Differentiation and Alleviated Dexamethasone-Induced Insulin Resistance in 3T3-L1 adipocytes. Dexamethasone 82-95 insulin Homo sapiens 104-111 27362350-6 2016 We found that dexamethasone treatment significantly increased the following fasting serum levels (P<0.05): HDL, LDL, total cholesterol, triglycerides, glucose, and insulin. Dexamethasone 14-27 insulin Homo sapiens 167-174 27362350-7 2016 In addition, dexamethasone increased insulin resistance (HOMA-IR>3.4) from 8% to 85% (P<0.01). Dexamethasone 13-26 insulin Homo sapiens 37-44 27208730-5 2016 The glucocorticoid receptor (GcR) antagonist, mifepristone (10muM) prevented dexamethasone from inhibiting insulin"s action. Dexamethasone 77-90 insulin Homo sapiens 107-114 27208730-6 2016 Strikingly, this anti-insulin action of dexamethasone was also blocked by two CB1 cannabinoid receptor (CB1R) antagonists, O-2050 (500nM) and SR141716A (500nM), as well as by tetrahydrolipstatin (10muM), an inhibitor of diacylglycerol lipases-the enzymes responsible for the synthesis of the endocannabinoid, 2-arachidonoyl-glycerol (2-AG). Dexamethasone 40-53 insulin Homo sapiens 22-29 26039155-8 2015 Some of the effects of dexamethasone treatment on the maternal and fetal RAS were associated with altered insulin and thyroid hormone activity. Dexamethasone 23-36 insulin Homo sapiens 106-113 25748606-4 2015 RESULTS: After dexamethasone treatment, all 19 participants had increased insulin resistance (HOMA-IR and insulin sensitivity index [M/I] values) and 2 h plasma glucose concentrations, while beta cell function indices generally increased according to the increased resistance. Dexamethasone 15-28 insulin Homo sapiens 74-81 25748606-4 2015 RESULTS: After dexamethasone treatment, all 19 participants had increased insulin resistance (HOMA-IR and insulin sensitivity index [M/I] values) and 2 h plasma glucose concentrations, while beta cell function indices generally increased according to the increased resistance. Dexamethasone 15-28 insulin Homo sapiens 106-113 25321387-14 2014 CONCLUSIONS: Multiple-dose insulin therapy initiated at 1-1.2 units/kg/day, distributed as 25% basal and 75% prandial, reduced hyperglycemia in patients who were receiving high-dose dexamethasone as part of hyper-CVAD. Dexamethasone 182-195 insulin Homo sapiens 27-34 25503565-4 2015 Here, we compare cell autonomous models of insulin resistance induced by the cytokine tumour necrosis factor-alpha or by the steroid dexamethasone to construct detailed transcriptional and epigenomic maps associated with cellular insulin resistance. Dexamethasone 133-146 insulin Homo sapiens 230-237 25185805-10 2014 Western blot analysis indicates insulin produced similar activation of Akt Ser(473) and rpS6 Ser(240/244) in the ventral hypothalamus of control and dexamethasone-treated rats. Dexamethasone 149-162 insulin Homo sapiens 32-39 25185805-8 2014 Similarly, injection of insulin into the lateral ventricle or locally within the arcuate nucleus (ARC) significantly increased lumbar SNA in control rats but this response was absent in rats given access to dexamethasone. Dexamethasone 207-220 insulin Homo sapiens 24-31 25185805-11 2014 Collectively, these findings suggest that dexamethasone attenuates the sympathoexcitatory actions of insulin through a disruption of ARC neuronal function downstream of Akt or mammalian target of rapamycin (mTOR) signaling. Dexamethasone 42-55 insulin Homo sapiens 101-108 25089237-0 2014 Effects of Traditional Chinese Medicinal Plants on Anti-insulin Resistance Bioactivity of DXMS-Induced Insulin Resistant HepG2 Cells. Dexamethasone 90-94 insulin Homo sapiens 56-63 24997500-1 2014 OBJECTIVE: To study effects of dexamethasone on gene expression in human adipose tissue aiming to identify potential novel mechanisms for glucocorticoid-induced insulin resistance. Dexamethasone 31-44 insulin Homo sapiens 161-168 24997500-9 2014 CONCLUSIONS: Dexamethasone exposure promotes expression of FKBP5 in adipose tissue, a gene that may be implicated in glucocorticoid-induced insulin resistance. Dexamethasone 13-26 insulin Homo sapiens 140-147 24593222-4 2014 Insulin/Dex-loaded PLGA MS (Insulin/Dex MS) were prepared using both single and double emulsion/solvent extraction techniques. Dexamethasone 8-11 insulin Homo sapiens 28-35 25089237-0 2014 Effects of Traditional Chinese Medicinal Plants on Anti-insulin Resistance Bioactivity of DXMS-Induced Insulin Resistant HepG2 Cells. Dexamethasone 90-94 insulin Homo sapiens 103-110 25089237-4 2014 The biological activity of 16 medicinal plants was tested on dexamethasone (DXMS)-induced insulin resistant HepG2 cells. Dexamethasone 61-74 insulin Homo sapiens 90-97 25089237-4 2014 The biological activity of 16 medicinal plants was tested on dexamethasone (DXMS)-induced insulin resistant HepG2 cells. Dexamethasone 76-80 insulin Homo sapiens 90-97 25089237-5 2014 The result shows that 11 of the 16 medicinal plants enhanced glucose uptake of DXMS-induced insulin resistant HepG2 cells, thereby demonstrating their ability to increase insulin sensitivity, other five medicinal plants including Astragalus membranaceus were found ineffective. Dexamethasone 79-83 insulin Homo sapiens 92-99 25089237-5 2014 The result shows that 11 of the 16 medicinal plants enhanced glucose uptake of DXMS-induced insulin resistant HepG2 cells, thereby demonstrating their ability to increase insulin sensitivity, other five medicinal plants including Astragalus membranaceus were found ineffective. Dexamethasone 79-83 insulin Homo sapiens 171-178 24955299-4 2014 Furthermore, this compound can also restore the glucose absorption in DXMS-induced insulin resistant 3T3-L1 cells. Dexamethasone 70-74 insulin Homo sapiens 83-90 23521139-2 2013 Laminitis-prone ponies have a greater serum insulin response to dexamethasone administration than normal ponies in the summer, but the response during different seasons is unknown. Dexamethasone 64-77 insulin Homo sapiens 44-51 21822910-5 2014 One patient receiving corticosteroid injections had a transient increase in hemoglobin A1c (+0.6% above baseline), and one patient given a one time dose of oral dexamethasone exhibited hyperglycemia despite high insulin (>200 mU/L) and C-peptide (15.3 ng/mL) production on an oral glucose tolerance test. Dexamethasone 161-174 insulin Homo sapiens 212-219 23521139-3 2013 OBJECTIVE: To test the hypothesis that previously laminitic ponies have a greater insulin response to dexamethasone than normal ponies, which is present during all seasons. Dexamethasone 102-115 insulin Homo sapiens 82-89 23521139-9 2013 RESULTS: Insulin concentrations pre- and post dexamethasone were significantly higher in previously laminitic ponies than in normal ponies during spring 2009 and summer 2008, but there was no difference between groups in spring 2010, summer 2010, autumn 2009 or winter 2008. Dexamethasone 46-59 insulin Homo sapiens 9-16 23859018-4 2013 The results suggest that RBP4 significantly suppresses the differentiation of porcine preadipocytes into adipocytes, including those treated with the hormone cocktail methylisobutylxanthine-dexamethasone-insulin. Dexamethasone 190-203 insulin Homo sapiens 204-211 23337144-6 2013 On the last day of dexamethasone administration, the insulin requirement was 49 +- 29 units/day in the SSI group and 122 +- 39 units/day in the BBI group (P <.001). Dexamethasone 19-32 insulin Homo sapiens 53-60 22998134-6 2013 RESULTS: Patients on dexamethasone had lower androgens and ACTH but greater insulin resistance compared with those receiving hydrocortisone or prednisolone. Dexamethasone 21-34 insulin Homo sapiens 76-83 22998134-7 2013 Dexamethasone dose and once daily administration were associated with insulin resistance. Dexamethasone 0-13 insulin Homo sapiens 70-77 22998134-12 2013 CONCLUSIONS: In adults with congenital adrenal hyperplasia, dexamethasone use was associated with lower androgens but greater insulin resistance, and increasing glucocorticoid dose associated with increased blood pressure, poor disease control and mutation severity. Dexamethasone 60-73 insulin Homo sapiens 126-133 23505190-10 2013 Post-dexamethasone cortisol levels were weak to moderately correlated with fasting insulin (rs = -0.31, P = 0.01) and HOMA-IR (rs = -0.31, P = 0.01) in men and systolic (rs = 0.18, P = 0.02) and diastolic BP (rs = 0.20, P = 0.009) in women. Dexamethasone 5-18 insulin Homo sapiens 83-90 23337144-1 2013 OBJECTIVE: To compare the response to different insulin regimens for management of hyperglycemia in diabetic patients with hematologic malignancies who are receiving dexamethasone. Dexamethasone 166-179 insulin Homo sapiens 48-55 20840879-0 2011 Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Dexamethasone 48-61 insulin Homo sapiens 18-25 22949029-6 2012 Cotreatment with DEX blocked TNF induction of basal lipolysis and insulin resistance by antagonizing TNF stimulation of PKA-mediated phosphorylation of hormone-sensitive lipase (HSL) at Ser563 and Ser660 and perilipin. Dexamethasone 17-20 insulin Homo sapiens 66-73 22223069-4 2012 RESULTS: We identified two different but physiologically relevant IR models characterized by attenuated insulin-induced phosphorylation of insulin receptor substrate-1 and AKT in TNF-alpha- or DEX-treated HepG2 cells. Dexamethasone 193-196 insulin Homo sapiens 104-111 22223069-4 2012 RESULTS: We identified two different but physiologically relevant IR models characterized by attenuated insulin-induced phosphorylation of insulin receptor substrate-1 and AKT in TNF-alpha- or DEX-treated HepG2 cells. Dexamethasone 193-196 insulin Homo sapiens 139-146 22536234-13 2012 The effects on maternal fasting blood glucose and insulin levels of dexamethasone administrated to promote fetal lung maturation correlated with embryo number and the presence of IGT. Dexamethasone 68-81 insulin Homo sapiens 50-57 22536436-0 2012 Tau phosphorylation and mu-calpain activation mediate the dexamethasone-induced inhibition on the insulin-stimulated Akt phosphorylation. Dexamethasone 58-71 insulin Homo sapiens 98-105 23154295-5 2011 RESULTS: Both short- (24 h) and long-term (7 days) treatment of chub-s7 cells with dexamethasone (Dex) (0.5 muM) increased insulin-stimulated pTyr612IRS1 and pSer473akt/PKB, consistent with insulin sensitization. Dexamethasone 83-96 insulin Homo sapiens 123-130 23154295-5 2011 RESULTS: Both short- (24 h) and long-term (7 days) treatment of chub-s7 cells with dexamethasone (Dex) (0.5 muM) increased insulin-stimulated pTyr612IRS1 and pSer473akt/PKB, consistent with insulin sensitization. Dexamethasone 83-96 insulin Homo sapiens 190-197 23154295-5 2011 RESULTS: Both short- (24 h) and long-term (7 days) treatment of chub-s7 cells with dexamethasone (Dex) (0.5 muM) increased insulin-stimulated pTyr612IRS1 and pSer473akt/PKB, consistent with insulin sensitization. Dexamethasone 98-101 insulin Homo sapiens 123-130 23154295-5 2011 RESULTS: Both short- (24 h) and long-term (7 days) treatment of chub-s7 cells with dexamethasone (Dex) (0.5 muM) increased insulin-stimulated pTyr612IRS1 and pSer473akt/PKB, consistent with insulin sensitization. Dexamethasone 98-101 insulin Homo sapiens 190-197 23154295-7 2011 However, treatment with both high-dose insulin and Dex in combination still caused insulin sensitization. Dexamethasone 51-54 insulin Homo sapiens 83-90 22784841-4 2012 RESULTS: Before administration of dexamethasone or placebo, area under the curve (AUC) for glucose and homeostasis model assessment of insulin resistance were higher, and the Matsuda and disposition indices were lower, in the prediabetic versus the NGT group. Dexamethasone 34-47 insulin Homo sapiens 135-142 22784841-5 2012 In both NGT and prediabetic groups treated with dexamethasone, glucose and insulin values at fasting and during OGTT were increased in comparison with placebo-treated groups at 24 hours (P = .001). Dexamethasone 48-61 insulin Homo sapiens 75-82 22784841-6 2012 Dexamethasone treatment in both study groups increased homeostasis model assessment of insulin resistance and AUC glucose and decreased the Matsuda index (P = .001). Dexamethasone 0-13 insulin Homo sapiens 87-94 22286551-3 2012 glucose test and a mixed meal to evaluate the incretin effect before and after treatment with dexamethasone to increase insulin resistance. Dexamethasone 94-107 insulin Homo sapiens 120-127 21244702-10 2011 Adrenalectomy combined with the synthetic glucocorticoid dexamethasone treatment resulted in increased glucose and insulin levels, decreased serum adiponectin levels, reduced adiponectin mRNA in epididymal adipose tissue, reduction of adipoR2 mRNA by 7-fold in muscle and reduced adipoR1 and adipoR2 protein levels in muscle. Dexamethasone 57-70 insulin Homo sapiens 115-122 20840879-1 2011 Theca cells with dexamethasone-induced insulin resistance showed defective glucose uptake and excessive testosterone production, both of which were effectively antagonized by berberine. Dexamethasone 17-30 insulin Homo sapiens 39-46 21897647-0 2011 Effect of insulin plant leaves on dexamethasone-induced hyperglycemia. Dexamethasone 34-47 insulin Homo sapiens 10-17 20839152-6 2010 After dexamethasone treatment African Americans were significantly more hyperinsulinemic after a meal as indicated by higher peak insulin (p=0.02) and postprandial insulin areas under the curve (p=0.006) than Caucasians. Dexamethasone 6-19 insulin Homo sapiens 77-84 22022575-6 2011 Low dose Dexamethasone pre-treatment (5 nM) of Chub-S7 cells augmented the ability of insulin to stimulate lipogenesis and there was no evidence of adipose tissue insulin resistance in primary sc cells. Dexamethasone 9-22 insulin Homo sapiens 86-93 20839152-6 2010 After dexamethasone treatment African Americans were significantly more hyperinsulinemic after a meal as indicated by higher peak insulin (p=0.02) and postprandial insulin areas under the curve (p=0.006) than Caucasians. Dexamethasone 6-19 insulin Homo sapiens 130-137 20839152-7 2010 Additionally, African Americans were more insulin resistant than Caucasian Americans under both placebo and dexamethasone as determined by fasting insulin and HOMA (p=0.05). Dexamethasone 108-121 insulin Homo sapiens 147-154 20350917-1 2010 OBJECTIVE: To determine the dose-response and time course of action of a single dose of dexamethasone on plasma glucose and insulin dynamics in healthy adults. Dexamethasone 88-101 insulin Homo sapiens 124-131 20350917-12 2010 Twenty-four hours after 8-mg dexamethasone, there was a 2.2- and 1.5-fold increase in homeostasis model assessment of insulin resistance and homeostasis model assessment of beta cells, respectively, and a 2.5-fold decrease in the Matsuda sensitivity index. Dexamethasone 29-42 insulin Homo sapiens 118-125 20350917-13 2010 CONCLUSIONS: A single oral dose of 8-mg dexamethasone increases blood glucose, insulin, and C-peptide levels maximally at 24 hours, 1 hour following 75-g OGTT. Dexamethasone 40-53 insulin Homo sapiens 79-86 20839152-8 2010 Waist circumference correlated with post-dexamethasone insulin AUC and HOMA in Caucasian Americans (p<0.05), but none of the body composition measures were predictive of IR for African Americans. Dexamethasone 41-54 insulin Homo sapiens 55-62 20839152-9 2010 African Americans are more sensitive to glucocorticoids (dexamethasone) than Caucasian Americans, as indicated by significantly greater peak insulin and postprandial insulin areas under the curve. Dexamethasone 57-70 insulin Homo sapiens 141-148 20839152-9 2010 African Americans are more sensitive to glucocorticoids (dexamethasone) than Caucasian Americans, as indicated by significantly greater peak insulin and postprandial insulin areas under the curve. Dexamethasone 57-70 insulin Homo sapiens 166-173 20022950-1 2010 Insulin resistance can occur in response to many different external insults, including chronic exposure to insulin itself as well as other agonists such as dexamethasone. Dexamethasone 156-169 insulin Homo sapiens 0-7 20022950-9 2010 We conclude that in chronic insulin- and dexamethasone-treated cells, acute activation with insulin itself is required to activate a feedforward inhibitory pathway likely emanating from phosphatidylinositol 3-kinase that converges on a target downstream of Akt to cause insulin resistance. Dexamethasone 41-54 insulin Homo sapiens 92-99 20022950-9 2010 We conclude that in chronic insulin- and dexamethasone-treated cells, acute activation with insulin itself is required to activate a feedforward inhibitory pathway likely emanating from phosphatidylinositol 3-kinase that converges on a target downstream of Akt to cause insulin resistance. Dexamethasone 41-54 insulin Homo sapiens 92-99 19675138-5 2009 RESULTS: Dexamethasone decreased insulin-stimulated glucose uptake, decreased IRS1 mRNA and protein expression, and increased inactivating pSer(307) insulin receptor substrate (IRS)-1. Dexamethasone 9-22 insulin Homo sapiens 33-40 19579180-8 2009 These data indicate a differential AMPK-dependent regulation of G6Pase gene expression by insulin and metformin under basal and dexamethasone/cAMP-stimulated conditions. Dexamethasone 128-141 insulin Homo sapiens 90-97 19579180-4 2009 We have found that both metformin and insulin inhibit the basal and dexamethasone/cAMP-stimulated G6Pase promoter activity in hepatoma cells. Dexamethasone 68-81 insulin Homo sapiens 38-45 19474523-4 2009 In this study, we used two cellular models of insulin resistance, one induced by treatment with tumor necrosis factor-alpha (TNF-alpha) and the other with the glucocorticoid dexamethasone. Dexamethasone 174-187 insulin Homo sapiens 46-53 19852296-0 2009 [Of berberine and puerarin on dexamethasone-induced insulin resistance in porcine ovarian thecal cells]. Dexamethasone 30-43 insulin Homo sapiens 52-59 19852296-1 2009 OBJECTIVE: To explore the direct contribution of dexamethasone (Dex) for insulin resistance inducing in thecal cells and effects of berberine (Ber) and puerarin (Pue). Dexamethasone 49-62 insulin Homo sapiens 73-80 19852296-1 2009 OBJECTIVE: To explore the direct contribution of dexamethasone (Dex) for insulin resistance inducing in thecal cells and effects of berberine (Ber) and puerarin (Pue). Dexamethasone 64-67 insulin Homo sapiens 73-80 19852296-3 2009 Insulin resistance of thecal cells was induced by Dex treatment for 48 h. Then the glucose utilization ratio of thecal cells was detected. Dexamethasone 50-53 insulin Homo sapiens 0-7 18672234-6 2009 Insulin resistance was induced in theca cells without (Con) or with dexamethasone (Dex); cells were further treated by troglitazone (Tro) and metformin (Met) in IR cells or by vehicle only in IR and Con cells. Dexamethasone 68-81 insulin Homo sapiens 0-7 18672234-6 2009 Insulin resistance was induced in theca cells without (Con) or with dexamethasone (Dex); cells were further treated by troglitazone (Tro) and metformin (Met) in IR cells or by vehicle only in IR and Con cells. Dexamethasone 83-86 insulin Homo sapiens 0-7 18672234-11 2009 CONCLUSION(S): Insulin resistance induced by Dex could directly exaggerate androgenic potential within theca cells, suggesting the possible involvement of this ovarian metabolic phenotype in PCOS hyperandrogenism. Dexamethasone 45-48 insulin Homo sapiens 15-22 19460735-9 2009 CONCLUSION: A cell model of insulin resistance has been established in 3T3-L1 adipocytes by dexamethasone exposure. Dexamethasone 92-105 insulin Homo sapiens 28-35 18812026-0 2008 Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Dexamethasone 65-78 insulin Homo sapiens 87-94 18363889-0 2008 Adiponectin, skeletal muscle adiponectin receptor expression and insulin resistance following dexamethasone. Dexamethasone 94-107 insulin Homo sapiens 65-72 18363889-8 2008 However following dexamethasone which increased insulin resistance, the relationship between adiponectin and the biochemical measures was lost. Dexamethasone 18-31 insulin Homo sapiens 48-55 18812026-4 2008 Moreover, BFOV enhanced the action of insulin and completely prevented the development of insulin resistance induced by dexamethasone, leading to glucose consumption equal to that by normal cells. Dexamethasone 120-133 insulin Homo sapiens 90-97 18812026-6 2008 These findings suggest that BFOV prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes by enhancing expression of IRS-1 and GLUT4 mRNA. Dexamethasone 55-68 insulin Homo sapiens 77-84 18429991-3 2008 Adult male Wistar rats were made insulin resistant by daily administration of dexamethasone (DEX; 1mg/kg, i.p.) Dexamethasone 78-91 insulin Homo sapiens 33-40 18501893-2 2008 The addition of a PPARgamma agonist to the Isobutylmethylxanthine/Dexamethasone/Insulin differentiation cocktail increased leptin mRNA levels by 5-fold, maintained insulin sensitivity, and yielded mature phenotype in cultured adipocytes. Dexamethasone 66-79 insulin Homo sapiens 164-171 18777500-16 2008 Dexamethasone administration resulted in an increase in fasting insulin (from 11.6 +/- 6.8 to 17.1 +/- 7.2 muU/ml; p = 0.003), and an increase in HOMA (from 2.73 +/- 1.74 to 4.02 +/- 2.27; p = 0.015), although without a significant change in RBP-4 levels (119 +/- 26.8 vs. 117.5 +/- 24.8 mg/ml, p = ns). Dexamethasone 0-13 insulin Homo sapiens 64-71 18777500-20 2008 CONCLUSIONS: RBP-4 levels do not change during oral glucose tolerance test or after a dexamethasone-induced increase in insulin resistance. Dexamethasone 86-99 insulin Homo sapiens 120-127 18437349-0 2008 Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans. Dexamethasone 99-112 insulin Homo sapiens 74-81 18437349-3 2008 Insulin resistance was induced by dexamethasone (15 mg given over 3 days) in nine healthy women (age 67 years, BMI 25.2+/-3.4 kg/m(2), fasting glucose 5.1+/-0.4 mmol/l, fasting insulin 46+/-6 pmol/l). Dexamethasone 34-47 insulin Homo sapiens 0-7 18437349-6 2008 RESULTS: As an indication of insulin resistance, dexamethasone increased fasting insulin (to 75+/-8 pmol/l, p<0.001) without significantly affecting fasting glucose. Dexamethasone 49-62 insulin Homo sapiens 29-36 18437349-6 2008 RESULTS: As an indication of insulin resistance, dexamethasone increased fasting insulin (to 75+/-8 pmol/l, p<0.001) without significantly affecting fasting glucose. Dexamethasone 49-62 insulin Homo sapiens 81-88 18437349-8 2008 During dexamethasone-induced insulin resistance, trimethaphan reduced the insulin response to arginine at all three glucose levels. Dexamethasone 7-20 insulin Homo sapiens 29-36 17556533-8 2007 Taken together, it is conceivable that BMOV and/or dexamethasone modulate insulin signaling by acting differentially on the components of the insulin signaling network. Dexamethasone 51-64 insulin Homo sapiens 74-81 17975996-0 2007 Effect of dietary fructans and dexamethasone administration on the insulin response of ponies predisposed to laminitis. Dexamethasone 31-44 insulin Homo sapiens 67-74 17953366-0 2007 [Mechanism of rosiglitasone to improve glucose-uptake of 3T3-L1 adipocyte with insulin resistance induced by dexamethasone and insulin]. Dexamethasone 109-122 insulin Homo sapiens 79-86 17953366-1 2007 OBJECTIVE: To study the mechanism of rosiglitasone to improve glucose-uptake of 3T3-L1 adipocyte with insulin resistance induced by dexamethasone and insulin. Dexamethasone 132-145 insulin Homo sapiens 102-109 17953366-2 2007 METHODS: Insulin resistance was induced to 3T3-L1 adipocyte after chronic treatment of dexamethasone and insulin. Dexamethasone 87-100 insulin Homo sapiens 9-16 18437349-9 2008 The augmentation of the arginine-induced insulin responses by dexamethasone-induced insulin resistance was reduced by trimethaphan by 48+/-6% at fasting glucose, 61+/-8% at 13-15 mmol/l glucose and 62+/-8% at >28 mmol/l glucose (p<0.001 for all). Dexamethasone 62-75 insulin Homo sapiens 41-48 18437349-9 2008 The augmentation of the arginine-induced insulin responses by dexamethasone-induced insulin resistance was reduced by trimethaphan by 48+/-6% at fasting glucose, 61+/-8% at 13-15 mmol/l glucose and 62+/-8% at >28 mmol/l glucose (p<0.001 for all). Dexamethasone 62-75 insulin Homo sapiens 84-91 18437349-11 2008 CONCLUSIONS/INTERPRETATIONS: Autonomic mechanisms contribute to the adaptative increase in insulin secretion in dexamethasone-induced insulin resistance in healthy participants. Dexamethasone 112-125 insulin Homo sapiens 91-98 17408773-0 2008 Dexamethasone-eluting stents for the prevention of in-stent restenosis: evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients. Dexamethasone 0-13 insulin Homo sapiens 110-117 17408773-0 2008 Dexamethasone-eluting stents for the prevention of in-stent restenosis: evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients. Dexamethasone 0-13 insulin Homo sapiens 136-143 17408773-18 2008 Our data suggest a differential effect of dexamethasone-eluting stents in insulin-dependent compared to non-insulin-dependent DM. Dexamethasone 42-55 insulin Homo sapiens 74-81 17370312-4 2007 The XOR reporter gene was activated by the epidermal growth factors (EGF), prolactin, and dexamethasone and by the acute phase cytokines (APC) IL-1, IL-6, and TNFalpha as previously reported for its native gene, and insulin further stimulated activation induced with acute phase cytokines or growth factors. Dexamethasone 90-103 insulin Homo sapiens 216-223 17556533-8 2007 Taken together, it is conceivable that BMOV and/or dexamethasone modulate insulin signaling by acting differentially on the components of the insulin signaling network. Dexamethasone 51-64 insulin Homo sapiens 142-149 17556533-9 2007 We also consider that the observed dexamethasone-mediated modulation of insulin receptor kinase in BMOV-treated 3T3-L1 cells probably occurs through the activation/deactivation of some mechanism which needs further studies for proper characterization. Dexamethasone 35-48 insulin Homo sapiens 72-79 17940983-0 2007 Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans. Dexamethasone 80-93 insulin Homo sapiens 114-121 17940983-15 2007 Dexamethasone administration resulted in an increase in fasting insulin (from 11.5 +/- 6.9 to 16.9 +/- 7.6 microU/mL; p = 0.011) and an increase in HOMA (from 2.73 +/- 1.74 to 4.02 +/- 2.27; p = 0.015), albeit without a significant change in serum visfatin concentrations (61.1 +/- 19.8 vs. 68.3 +/- 19.4 ng/mL, p = ns). Dexamethasone 0-13 insulin Homo sapiens 64-71 17940983-19 2007 Dexamethasone administration (4 mg/48 hours) induces an increase in insulin resistance, although without significant change in serum visfatin concentrations. Dexamethasone 0-13 insulin Homo sapiens 68-75 16469141-2 2006 We studied whether n-3 long-chain PUFA could prevent insulin resistance induced by dexamethasone (a glucocorticoid) in healthy human volunteers. Dexamethasone 83-96 insulin Homo sapiens 53-60 16868225-4 2006 Dexamethasone alone caused hyperinsulinemia, increased glucose, decreased glucose disposal, and reduced insulin-induced suppression of hepatic glucose production as determined by hyperinsulinemic euglycemic clamp and increased systolic blood pressure as determined by ambulatory monitoring, features associated with an insulin-resistant state. Dexamethasone 0-13 insulin Homo sapiens 32-39 16574792-7 2006 DEX inhibited insulin signaling through a GR-dependent (RU486 sensitive) and transcription-independent (actinomycin D insensitive) mechanism. Dexamethasone 0-3 insulin Homo sapiens 14-21 16648290-6 2006 In contrast, both single and multiple courses of antenatal Dex were associated with an increase in the extensor digitorum lateralis and biceps femoris muscle GLUT 4 (insulin-responsive) concentrations (P < 0.05). Dexamethasone 59-62 insulin Homo sapiens 166-173 16984253-0 2006 Short-term dexamethasone administration does not alter serum adiponectin or resistin concentrations in overweight and obese subjects despite an increase in insulin resistance. Dexamethasone 11-24 insulin Homo sapiens 156-163 17375502-8 2006 A week following cessation of the dexamethasone and terbutaline, her insulin requirements dramatically decreased. Dexamethasone 34-47 insulin Homo sapiens 69-76 17375502-9 2006 We conclude that in pregnant patients with underlying insulin resistance and strong family history of diabetes, the use of agents that antagonize insulin action, such as dexamethasone and terbutaline, can result in massive insulin resistance. Dexamethasone 170-183 insulin Homo sapiens 54-61 17375502-9 2006 We conclude that in pregnant patients with underlying insulin resistance and strong family history of diabetes, the use of agents that antagonize insulin action, such as dexamethasone and terbutaline, can result in massive insulin resistance. Dexamethasone 170-183 insulin Homo sapiens 146-153 17375502-9 2006 We conclude that in pregnant patients with underlying insulin resistance and strong family history of diabetes, the use of agents that antagonize insulin action, such as dexamethasone and terbutaline, can result in massive insulin resistance. Dexamethasone 170-183 insulin Homo sapiens 146-153 16965635-6 2006 RESULTS: Mean changes in all hormones were no different between treatment arms, despite dexamethasone-related increases in body weight, blood pressure, HDL cholesterol and insulin. Dexamethasone 88-101 insulin Homo sapiens 172-179 16965635-7 2006 Changes in calculated indices of insulin sensitivity (HOMA-S, insulin sensitivity index) were strongly related to dexamethasone treatment (p < 0.001). Dexamethasone 114-127 insulin Homo sapiens 33-40 16965635-7 2006 Changes in calculated indices of insulin sensitivity (HOMA-S, insulin sensitivity index) were strongly related to dexamethasone treatment (p < 0.001). Dexamethasone 114-127 insulin Homo sapiens 62-69 16002526-5 2005 Conversely, insulin inhibits basal promoter activity by 40% and Dex-stimulated promoter activity by 65%, indicating that glucocorticoids enhance the ability of insulin to suppress promoter activity. Dexamethasone 64-67 insulin Homo sapiens 12-19 16002526-5 2005 Conversely, insulin inhibits basal promoter activity by 40% and Dex-stimulated promoter activity by 65%, indicating that glucocorticoids enhance the ability of insulin to suppress promoter activity. Dexamethasone 64-67 insulin Homo sapiens 160-167 15582718-8 2005 DEX-treated rats remained euglycemic, but their insulin levels were significantly increased, indicating an incipient insulin resistance. Dexamethasone 0-3 insulin Homo sapiens 48-55 15604115-1 2005 Phosphoenolpyruvate carboxykinase (PEPCK) transcription is induced by cAMP/protein kinase A (PKA) and glucocorticoids [dexamethasone (Dex)] and is inhibited by insulin to regulate blood glucose. Dexamethasone 134-137 insulin Homo sapiens 160-167 15582718-8 2005 DEX-treated rats remained euglycemic, but their insulin levels were significantly increased, indicating an incipient insulin resistance. Dexamethasone 0-3 insulin Homo sapiens 117-124 15582718-9 2005 Although BIM-23627 itself tended to increase insulin concentration in saline-treated rats, its administration to DEX-treated rats reduced insulin levels (saline: 25+/-3; DEX: 55+/-16*; DEX+BIM-23627: 34+/-5; BIM-23627: 38+/-7 microIU/ml; *P<0.05 vs. saline), apparently improving the degree of insulin sensitivity. Dexamethasone 113-116 insulin Homo sapiens 138-145 15582718-9 2005 Although BIM-23627 itself tended to increase insulin concentration in saline-treated rats, its administration to DEX-treated rats reduced insulin levels (saline: 25+/-3; DEX: 55+/-16*; DEX+BIM-23627: 34+/-5; BIM-23627: 38+/-7 microIU/ml; *P<0.05 vs. saline), apparently improving the degree of insulin sensitivity. Dexamethasone 113-116 insulin Homo sapiens 138-145 15800288-1 2005 OBJECTIVE: In healthy lean individuals, changes in insulin sensitivity occurring as a consequence of a 2-day dexamethasone administration are compensated for by changes in insulin secretion, allowing glucose homeostasis to be maintained. Dexamethasone 109-122 insulin Homo sapiens 51-58 15800288-8 2005 After dexamethasone, obese women had a 66% to 92% increase in plasma insulin concentrations but a 15.4% decrease in whole body glucose disposal. Dexamethasone 6-19 insulin Homo sapiens 69-76 15823722-5 2005 In dexamethasone-treated rats, high doses of this compound have been shown to markedly improve insulin sensitivity. Dexamethasone 3-16 insulin Homo sapiens 95-102 15531514-5 2004 Although IL-6 had no significant effects under basal conditions, culture with the combination of IL-6 and dex, compared with dex alone, for 2 d increased leptin in both depots [+95 +/- 30% (sc) and +67 +/- 19% (Om), P < 0.01]; IL-6 did not affect leptin production when added in the presence of insulin. Dexamethasone 106-109 insulin Homo sapiens 298-305 15100091-6 2004 IGF-I and insulin also blocked Dex induction of these E3s and several other atrophy-related genes ("atrogenes"). Dexamethasone 31-34 insulin Homo sapiens 10-17 14665448-2 2004 To determine whether the compensatory insulin secretory response to an increase in insulin resistance induced by the glucocorticoid dexamethasone differs in women with PCOS and control subjects, we studied 10 PCOS and 6 control subjects with normal glucose tolerance. Dexamethasone 132-145 insulin Homo sapiens 38-45 15525874-0 2004 Dexamethasone-induced insulin resistance shows no gender difference in healthy humans. Dexamethasone 0-13 insulin Homo sapiens 22-29 15525874-5 2004 RESULTS: Dexamethasone decreased insulin sensitivity to the same extent in men and women. Dexamethasone 9-22 insulin Homo sapiens 33-40 15525874-6 2004 The relative increases in insulin concentration observed after dexamethasone in the basal state, during the first phase of insulin release and at the two steps of hyperglycemia were similar in men and women. Dexamethasone 63-76 insulin Homo sapiens 26-33 14665448-2 2004 To determine whether the compensatory insulin secretory response to an increase in insulin resistance induced by the glucocorticoid dexamethasone differs in women with PCOS and control subjects, we studied 10 PCOS and 6 control subjects with normal glucose tolerance. Dexamethasone 132-145 insulin Homo sapiens 83-90 12641495-4 2003 Dexamethasone induces the expression of CCAAT/enhancer-binding protein (C/EBP) alpha, insulin promotes myocyte enhancer factor-2 DNA-binding activity and both combined produces a significant increase in C/EBPalpha DNA-binding activity. Dexamethasone 0-13 insulin Homo sapiens 86-93 15181089-7 2004 Dexamethasone treatment markedly inhibited (by approximately 50%; P < 0.05) both basal and insulin-stimulated glucose uptake in omental adipocytes but had no consistent effect in s.c. adipocytes. Dexamethasone 0-13 insulin Homo sapiens 94-101 15094069-11 2004 Inhibition of insulin transport across the BBB by dexamethasone could be the basis for the enhanced appetite seen with glucocorticoid treatments. Dexamethasone 50-63 insulin Homo sapiens 14-21 14966043-0 2004 Insulin induced increase in coronary flow reserve is abolished by dexamethasone in young men with uncomplicated type 1 diabetes. Dexamethasone 66-79 insulin Homo sapiens 0-7 14966043-5 2004 In contrast to non-diabetic patients dexamethasone pretreatment abolished the insulin induced increase in coronary flow reserve in diabetic patients (p < 0.05) leading to lower coronary flow reserve in diabetic than in non-diabetic patients (3.9 (0.6) v 7.1 (0.9), p < 0.05). Dexamethasone 37-50 insulin Homo sapiens 78-85 14966043-7 2004 Dexamethasone treatment abolished the insulin induced increase in coronary flow reserve in diabetic patients but not in healthy study participants, suggesting that sympathetic activation plays an important part in regulating insulin"s effects on myocardial perfusion in patients with type 1 diabetes. Dexamethasone 0-13 insulin Homo sapiens 38-45 14671204-2 2003 We investigated the effect of dexamethasone on insulin-stimulated glucose disposal and vasodilation in healthy males to test the hypothesis that a reduction in glucose disposal would be accompanied by a reduction in insulin action in the vasculature. Dexamethasone 30-43 insulin Homo sapiens 47-54 14671204-4 2003 Six days of dexamethasone therapy was associated with a 30% (95% confidence interval, 19.1-40.0%) fall in insulin sensitivity. Dexamethasone 12-25 insulin Homo sapiens 106-113 14671204-7 2003 By short-term exposure to high dose dexamethasone we were able to differentially affect the metabolic and vascular actions of insulin. Dexamethasone 36-49 insulin Homo sapiens 126-133 12919163-26 2003 While indices of insulin sensitivity measured during schedules 1, 2 and 3 did not achieve statistical significance, there was an obvious trend for greater insulin resistance to occur with schedules 3 using dexamethasone. Dexamethasone 206-219 insulin Homo sapiens 155-162 12824867-8 2003 Dexamethasone reduced both insulin- and SNP-stimulated glucose uptake with impairment of GLUT4 translocation. Dexamethasone 0-13 insulin Homo sapiens 27-34 12740452-0 2003 Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Dexamethasone 25-38 insulin Homo sapiens 47-54 12740452-8 2003 RESULTS: In all subjects, dexamethasone induced a decrease in insulin sensitivity and a proportionate increase in first-phase insulin secretion and in insulin concentrations at both steps of glycemia. Dexamethasone 26-39 insulin Homo sapiens 62-69 12740452-8 2003 RESULTS: In all subjects, dexamethasone induced a decrease in insulin sensitivity and a proportionate increase in first-phase insulin secretion and in insulin concentrations at both steps of glycemia. Dexamethasone 26-39 insulin Homo sapiens 126-133 12740452-8 2003 RESULTS: In all subjects, dexamethasone induced a decrease in insulin sensitivity and a proportionate increase in first-phase insulin secretion and in insulin concentrations at both steps of glycemia. Dexamethasone 26-39 insulin Homo sapiens 126-133 12740452-11 2003 DISCUSSION: Increased insulin secretion fully compensates dexamethasone-induced insulin resistance in skeletal muscle and adipose tissue but not in the liver. Dexamethasone 58-71 insulin Homo sapiens 22-29 12740452-11 2003 DISCUSSION: Increased insulin secretion fully compensates dexamethasone-induced insulin resistance in skeletal muscle and adipose tissue but not in the liver. Dexamethasone 58-71 insulin Homo sapiens 80-87 12740452-13 2003 The compensatory insulin secretion in response to insulin resistance can be assessed by means of a hyperglycemic clamp after a dexamethasone challenge. Dexamethasone 127-140 insulin Homo sapiens 17-24 12740452-13 2003 The compensatory insulin secretion in response to insulin resistance can be assessed by means of a hyperglycemic clamp after a dexamethasone challenge. Dexamethasone 127-140 insulin Homo sapiens 50-57 12351424-6 2002 Dexamethasone drastically impaired glucose tolerance, with fasting and 2-h OGTT insulin values increasing by 2.3-fold (P < 0.001) and 4.4-fold (P < 0.001) over baseline values, respectively. Dexamethasone 0-13 insulin Homo sapiens 80-87 12524663-8 2003 These data indicate that the release of leptin by human adipocytes cultured for 48 hours in a serum-free medium is comparable to that by explants of adipose tissue except that dexamethasone stimulation of leptin release requires the presence of insulin. Dexamethasone 176-189 insulin Homo sapiens 245-252 12351424-9 2002 Insulin-mediated FFA suppressibility (FFA decline at 30 min during clamp/FFA at time 0) was also markedly reduced by dexamethasone (P = 0.002). Dexamethasone 117-130 insulin Homo sapiens 0-7 12351424-12 2002 The same was true for the reversal of dexamethasone-induced insulin resistance by troglitazone, but not in response to troglitazone alone. Dexamethasone 38-51 insulin Homo sapiens 60-67 12039705-3 2002 The primary aim of this study was to determine whether the administration of a pulse of insulin with dexamethasone was sufficient to increase serum leptin in vivo in fasted human subjects. Dexamethasone 101-114 insulin Homo sapiens 88-95 12351424-17 2002 Specifically, troglitazone reverses both glucocorticoid-induced insulin resistance and impairment of glucose tolerance, prevents dexamethasone from impairing the antilipolytic action of insulin, and blocks the increase in leptin levels induced by dexamethasone. Dexamethasone 129-142 insulin Homo sapiens 186-193 12351424-18 2002 Even though changes in FFA suppressibility were correlated with dexamethasone-induced insulin resistance and its reversal by troglitazone, a cause-and-effect relationship cannot be established. Dexamethasone 64-77 insulin Homo sapiens 86-93 12370855-2 2002 Therefore, we measured electrolyte content and [3H]ouabain binding capacity of skeletal muscle in 20 relatives of type 2 diabetic patients and in 20 controls before and after glucose infusion and before and after treatment with dexamethasone, which decreases insulin sensitivity. Dexamethasone 228-241 insulin Homo sapiens 259-266 12039705-14 2002 CONCLUSIONS: With the permissive effect of dexamethasone, a single pulse of insulin triggered a rise in serum leptin in humans, even in the absence of transient hyperglycemia. Dexamethasone 43-56 insulin Homo sapiens 76-83 11517149-0 2001 Dexamethasone during late gestation exacerbates peripheral insulin resistance and selectively targets glucose-sensitive functions in beta cell and liver. Dexamethasone 0-13 insulin Homo sapiens 59-66 12005156-1 2002 The haemodynamic effects of the sympathetic nervous system (SNS) activations elicited by hypoglycaemia, acute alcohol administration, or insulin can be prevented by a pretreatment with dexamethasone in humans. Dexamethasone 185-198 insulin Homo sapiens 137-144 12005156-7 2002 After 2 days of dexamethasone treatment, whole body insulin-mediated glucose disposal was decreased by 40.8%. Dexamethasone 16-29 insulin Homo sapiens 52-59 12162603-1 2002 UNLABELLED: The aim of this study was to investigate the effect of postnatal systemic dexamethasone on serum leptin, insulin and hormones of the hypothalamic-pituitary-adrenal (HPA) axis in preterm, very low birthweight (VLBW) infants. Dexamethasone 86-99 insulin Homo sapiens 117-124 11517149-1 2001 We examined whether low-dose dexamethasone administration during late pregnancy modifies hepatic and/or peripheral insulin action or glucose-stimulated insulin secretion. Dexamethasone 29-42 insulin Homo sapiens 115-122 11517149-7 2001 Suppression of endogenous glucose production by insulin was enhanced by dexamethasone treatment, but insulin"s ability to promote glucose clearance was diminished. Dexamethasone 72-85 insulin Homo sapiens 48-55 11380499-12 2001 In addition, the duration between the last dose of antenatal dexamethasone and delivery significantly influenced the serum concentrations of leptin (r = - 0.27, P < 0.05), cortisol (r = 0.52, P < 0.001), plasma ACTH (r = 0.28, P < 0.05) and insulin:glucose ratio (r = - 0.27, P < 0.05) on the first day of life. Dexamethasone 61-74 insulin Homo sapiens 250-257 11520307-0 2001 Effect of vanadate on glycogen synthesis in dexamethasone-treated 3T3 adipocytes: evidence for a novel insulin sensitizing action. Dexamethasone 44-57 insulin Homo sapiens 103-110 11520307-2 2001 The present study was carried out to determine the insulin sensitizing action of vanadium using dexamethasone-treated 3T3 adipocytes as an in-vitro model of insulin resistance. Dexamethasone 96-109 insulin Homo sapiens 51-58 11520307-7 2001 At 100 microM, vanadate completely reversed dexamethasone-induced insulin resistance (by increasing the levels from 9.65 +/- 0.80 to 28.4 +/- 4.9 nmol/h). Dexamethasone 44-57 insulin Homo sapiens 66-73 11520307-12 2001 Glycogen synthesis in the normal and insulin-resistant adipocytes was stimulated by lithium, an inhibitor of glycogen synthase kinase 3 beta, suggesting the involvement of phosphorylation events in dexamethasone-induced insulin resistance. Dexamethasone 198-211 insulin Homo sapiens 37-44 11520307-12 2001 Glycogen synthesis in the normal and insulin-resistant adipocytes was stimulated by lithium, an inhibitor of glycogen synthase kinase 3 beta, suggesting the involvement of phosphorylation events in dexamethasone-induced insulin resistance. Dexamethasone 198-211 insulin Homo sapiens 220-227 11120457-7 2000 Following dexamethasone ingestion, plasma glucose remained stable in the control and new DM groups but increased by 240% in the chronic DM patients; in contrast, plasma insulin increased significantly in controls and new DM patients but not in patients with chronic DM. Dexamethasone 10-23 insulin Homo sapiens 169-176 11277867-8 2001 The transduced hepatocytes were shown to secrete immunoreactive proinsulin/insulin, which were stimulated by the concentrations of retinoic acid, dexamethasone and dbcAMP in the culture medium. Dexamethasone 146-159 insulin Homo sapiens 64-74 11277867-8 2001 The transduced hepatocytes were shown to secrete immunoreactive proinsulin/insulin, which were stimulated by the concentrations of retinoic acid, dexamethasone and dbcAMP in the culture medium. Dexamethasone 146-159 insulin Homo sapiens 67-74 11277867-9 2001 High conversion from proinsulin into insulin occurred when these cells were treated with dexamethasone and dbcAMP. Dexamethasone 89-102 insulin Homo sapiens 21-31 11277867-9 2001 High conversion from proinsulin into insulin occurred when these cells were treated with dexamethasone and dbcAMP. Dexamethasone 89-102 insulin Homo sapiens 24-31 11315852-0 2001 Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Dexamethasone 102-115 insulin Homo sapiens 62-69 11315852-0 2001 Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Dexamethasone 117-120 insulin Homo sapiens 62-69 11228263-1 2001 The objective of this study was to determine whether insulin administration would prevent the well-documented catabolic effect of dexamethasone given to preterm infants with chronic lung disease. Dexamethasone 130-143 insulin Homo sapiens 53-60 11062075-5 2000 Luciferase expression was also stimulated by the combination of dexamethasone and cAMP in HepG2 cells and this effect was inhibited by insulin. Dexamethasone 64-77 insulin Homo sapiens 135-142 11150359-9 2001 The infants in the dexamethasone group were less likely than those in the placebo group to be receiving oxygen supplementation 28 days after birth (P=0.004) or open-label dexamethasone (P=0.01), were more likely to have hypertension (P<0.001), and were more likely to be receiving insulin treatment for hyperglycemia (P=0.02). Dexamethasone 19-32 insulin Homo sapiens 284-291 11016454-0 2000 Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Dexamethasone 0-13 insulin Homo sapiens 22-29 11016454-2 2000 In this study, we investigated the mechanism of glucocorticoid-induced insulin resistance using 3T3-L1 adipocytes in which treatment with dexamethasone has been shown to impair the insulin-induced increase in glucose uptake. Dexamethasone 138-151 insulin Homo sapiens 71-78 11016454-2 2000 In this study, we investigated the mechanism of glucocorticoid-induced insulin resistance using 3T3-L1 adipocytes in which treatment with dexamethasone has been shown to impair the insulin-induced increase in glucose uptake. Dexamethasone 138-151 insulin Homo sapiens 181-188 11016454-4 2000 On the other hand, dexamethasone treatment did not alter the amount of GLUT4 protein in total cell lysates but decreased the insulin-stimulated GLUT4 translocation to the plasma membrane, which possibly caused decreased insulin-stimulated glucose uptake. Dexamethasone 19-32 insulin Homo sapiens 125-132 11016454-4 2000 On the other hand, dexamethasone treatment did not alter the amount of GLUT4 protein in total cell lysates but decreased the insulin-stimulated GLUT4 translocation to the plasma membrane, which possibly caused decreased insulin-stimulated glucose uptake. Dexamethasone 19-32 insulin Homo sapiens 220-227 11016454-8 2000 Despite protein expression and phosphorylation levels of IRS-1 being normalized, insulin-induced 2-deoxy-D-[3H]glucose uptake impaired by dexamethasone showed no significant improvement. Dexamethasone 138-151 insulin Homo sapiens 81-88 10807673-0 2000 Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes. Dexamethasone 35-48 insulin Homo sapiens 57-64 11082797-5 2000 However, fasting insulin levels were significantly lower in the AN group, both before and after dexamethasone therapy and their serum leptin levels were also significantly lower. Dexamethasone 96-109 insulin Homo sapiens 17-24 10872801-7 2000 The effects of cyclic AMP and dexamethasone were counteracted by 1 microM insulin. Dexamethasone 30-43 insulin Homo sapiens 74-81 10807673-9 2000 When cells were incubated with troglitazone and dexamethasone simultaneously for 6 days, troglitazone but not metformin completely prevented dexamethasone-induced insulin resistance. Dexamethasone 48-61 insulin Homo sapiens 163-170 10807673-9 2000 When cells were incubated with troglitazone and dexamethasone simultaneously for 6 days, troglitazone but not metformin completely prevented dexamethasone-induced insulin resistance. Dexamethasone 141-154 insulin Homo sapiens 163-170 10491753-0 1999 Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Dexamethasone 63-76 insulin Homo sapiens 0-7 10700531-1 2000 AIMS: This study was undertaken to determine the effects of a short-term dexamethasone treatment on hepatic sensitivities to insulin and glucagon. Dexamethasone 73-86 insulin Homo sapiens 125-132 10782559-0 1999 Dexamethasone-induced changes in FAD-glycerophosphate dehydrogenase mRNA, content and activity, and insulin release in human pancreatic islets. Dexamethasone 0-13 insulin Homo sapiens 100-107 10574511-8 1999 Plasma insulin increased (p = 0.02) in controls, but not in the diabetic patients, following dexamethasone. Dexamethasone 93-106 insulin Homo sapiens 7-14 10484052-2 1999 We investigated whether the mechanism differs for dexamethasone (dex)-induced insulin resistance in first-degree relatives of type 2 diabetics versus healthy control subjects by quantifying intracellular glucose processing in muscle biopsies taken before and after 5 days of dex treatment (4 mg/d) in 20 normal glucose-tolerant relatives of type 2 diabetic patients and 20 matched controls (age, 29.4 +/- 1.7 v 29.4 +/- 1.6 years; body mass index, 25.1 +/- 1.0 v 25.1 +/- 0.9 kg/m2). Dexamethasone 50-63 insulin Homo sapiens 78-85 10484052-2 1999 We investigated whether the mechanism differs for dexamethasone (dex)-induced insulin resistance in first-degree relatives of type 2 diabetics versus healthy control subjects by quantifying intracellular glucose processing in muscle biopsies taken before and after 5 days of dex treatment (4 mg/d) in 20 normal glucose-tolerant relatives of type 2 diabetic patients and 20 matched controls (age, 29.4 +/- 1.7 v 29.4 +/- 1.6 years; body mass index, 25.1 +/- 1.0 v 25.1 +/- 0.9 kg/m2). Dexamethasone 50-53 insulin Homo sapiens 78-85 10484052-2 1999 We investigated whether the mechanism differs for dexamethasone (dex)-induced insulin resistance in first-degree relatives of type 2 diabetics versus healthy control subjects by quantifying intracellular glucose processing in muscle biopsies taken before and after 5 days of dex treatment (4 mg/d) in 20 normal glucose-tolerant relatives of type 2 diabetic patients and 20 matched controls (age, 29.4 +/- 1.7 v 29.4 +/- 1.6 years; body mass index, 25.1 +/- 1.0 v 25.1 +/- 0.9 kg/m2). Dexamethasone 65-68 insulin Homo sapiens 78-85 10484052-10 1999 We postulate that the insulin resistance induced by dex in first-degree relatives of type 2 diabetic patients is associated with a preferential channeling of glucose into the glycolytic pathway (increased glucose oxidation and lactate production), probably associated with a preexisting downregulation of the glycosen synthase pathway. Dexamethasone 52-55 insulin Homo sapiens 22-29 11016454-11 2000 Thus, in conclusion, the GLUT1 decrease may be involved in the dexamethasone-induced decrease in basal glucose transport activity, and the mechanism of dexamethasone-induced insulin resistance in glucose transport activity (rather than the inhibition of phosphatidylinositol 3-kinase activation resulting from a decreased IRS-1 content) is likely to underlie impaired glucose transporter regulation. Dexamethasone 152-165 insulin Homo sapiens 174-181 10491753-0 1999 Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Dexamethasone 63-76 insulin Homo sapiens 98-105 10491753-5 1999 RESULTS: Dexamethasone reduced insulin sensitivity in both groups. Dexamethasone 9-22 insulin Homo sapiens 31-38 10491753-6 1999 Fasting insulin concentration increased by dexamethasone in high insulin sensitivity (72 +/- 10 vs 49 +/- 9 pmol/l, p = 0.043) but not in low insulin sensitivity (148 +/- 63 vs 145 +/- 78 pmol/l) whereas the fasting glucose concentration increased in low insulin sensitivity (6.5 +/- 0.8 vs 5.8 +/- 0.6 mmol/l, p = 0.043) but not in high insulin sensitivity (5.3 +/- 0.8 vs 5.3 +/- 0.6 mmol/l). Dexamethasone 43-56 insulin Homo sapiens 8-15 10491753-6 1999 Fasting insulin concentration increased by dexamethasone in high insulin sensitivity (72 +/- 10 vs 49 +/- 9 pmol/l, p = 0.043) but not in low insulin sensitivity (148 +/- 63 vs 145 +/- 78 pmol/l) whereas the fasting glucose concentration increased in low insulin sensitivity (6.5 +/- 0.8 vs 5.8 +/- 0.6 mmol/l, p = 0.043) but not in high insulin sensitivity (5.3 +/- 0.8 vs 5.3 +/- 0.6 mmol/l). Dexamethasone 43-56 insulin Homo sapiens 65-72 10491753-6 1999 Fasting insulin concentration increased by dexamethasone in high insulin sensitivity (72 +/- 10 vs 49 +/- 9 pmol/l, p = 0.043) but not in low insulin sensitivity (148 +/- 63 vs 145 +/- 78 pmol/l) whereas the fasting glucose concentration increased in low insulin sensitivity (6.5 +/- 0.8 vs 5.8 +/- 0.6 mmol/l, p = 0.043) but not in high insulin sensitivity (5.3 +/- 0.8 vs 5.3 +/- 0.6 mmol/l). Dexamethasone 43-56 insulin Homo sapiens 65-72 10491753-8 1999 Plasma insulin concentrations after raising glucose to 14 and more than 25 mmol/l and the insulin response to arginine at more than 25 mmol/l glucose were increased by dexamethasone in high insulin sensitivity (p < 0.05) but not changed by dexamethasone in low insulin sensitivity. Dexamethasone 168-181 insulin Homo sapiens 7-14 10491753-8 1999 Plasma insulin concentrations after raising glucose to 14 and more than 25 mmol/l and the insulin response to arginine at more than 25 mmol/l glucose were increased by dexamethasone in high insulin sensitivity (p < 0.05) but not changed by dexamethasone in low insulin sensitivity. Dexamethasone 168-181 insulin Homo sapiens 90-97 10491753-8 1999 Plasma insulin concentrations after raising glucose to 14 and more than 25 mmol/l and the insulin response to arginine at more than 25 mmol/l glucose were increased by dexamethasone in high insulin sensitivity (p < 0.05) but not changed by dexamethasone in low insulin sensitivity. Dexamethasone 168-181 insulin Homo sapiens 90-97 10491753-10 1999 CONCLUSION/INTERPRETATION: The results show that adaptation in islets function to dexamethasone-induced short-term reduction in insulin sensitivity is lacking in subjects with low inherent insulin sensitivity. Dexamethasone 82-95 insulin Homo sapiens 128-135 10491753-10 1999 CONCLUSION/INTERPRETATION: The results show that adaptation in islets function to dexamethasone-induced short-term reduction in insulin sensitivity is lacking in subjects with low inherent insulin sensitivity. Dexamethasone 82-95 insulin Homo sapiens 189-196 10231837-4 1999 Transfection of CAT constructs containing different segments of the insulin promoter into the pancreatic cell line, HIT T-15 2.2.2, demonstrated that dexamethasone decreased CAT activity in all constructs tested. Dexamethasone 150-163 insulin Homo sapiens 68-75 10231062-1 1999 OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. Dexamethasone 266-279 insulin Homo sapiens 124-131 10348493-7 1999 Culture with insulin and dexamethasone increased leptin expression vs. insulin alone. Dexamethasone 25-38 insulin Homo sapiens 71-78 9725819-5 1998 The combination of insulin and dexamethasone increased leptin mRNA and leptin secretion approximately two- to threefold in both depots at day 1 (P < 0.005 vs. basal or insulin) and maintained leptin expression throughout 7 days of culture. Dexamethasone 31-44 insulin Homo sapiens 171-178 9815000-8 1998 Plasma insulin concentrations were increased after 2 days of dexamethasone but not after a single dose of dexamethasone. Dexamethasone 61-74 insulin Homo sapiens 7-14 9815000-9 1998 In a second set of experiments, the effect of a single dose of dexamethasone on insulin sensitivity was assessed in six healthy humans during a 2-h euglycemic hyperinsulinemic clamp. Dexamethasone 63-76 insulin Homo sapiens 80-87 9610365-6 1998 The expression of PPAR alpha in cultured HAEC, which were induced by dexamethasone, was inhibited by insulin. Dexamethasone 69-82 insulin Homo sapiens 101-108 9688107-6 1998 RESULTS: Cells with a high affinity for laminin had the highest proportion of AD-3 and C/EBP-alpha positive cells and the highest proportion of fat cells after treatment with insulin +/- dexamethasone. Dexamethasone 187-200 insulin Homo sapiens 175-182 9827019-5 1998 Conversely, somatostatin (1 microM), adrenalin (1 microM), clonidine (2 microM), dexamethasone (0.4 microM), and 2-hydroxyestradiol (5 microM) decreased significantly the glucose-induced insulin release. Dexamethasone 81-94 insulin Homo sapiens 187-194 9666874-5 1998 The increase in leptin levels after dexamethasone administration was only partially related to the increase in plasma insulin concentrations. Dexamethasone 36-49 insulin Homo sapiens 118-125 9666874-7 1998 In multivariate analyses the relationship between post-treatment leptin and dexamethasone levels remained after adjustment for post-treatment insulin levels, BMI, waist:hip ratio (WHR) and age (men: P < 0.001; women: P = 0.001). Dexamethasone 76-89 insulin Homo sapiens 142-149 9468291-10 1998 The p70 ribosomal S6 kinase was not activated by dexamethasone and instead, dexamethasone attenuated the stimulation of this enzyme activity by insulin. Dexamethasone 76-89 insulin Homo sapiens 144-151 9506746-19 1998 Unlike dexamethasone, insulin had no direct stimulatory effect on ob gene expression and leptin secretion, and even prevented the positive response to dexamethasone by a cAMP-independent mechanism that remained functional despite insulin resistance. Dexamethasone 151-164 insulin Homo sapiens 22-29 9545024-3 1998 Six-day treatment with 10 or 850 nM insulin after FBS+Dex treatment resulted in a similar increase in leptin mRNA expression and morphological differentiation. Dexamethasone 54-57 insulin Homo sapiens 36-43 9468291-9 1998 Furthermore, dexamethasone down-regulated insulin receptor substrate-1 protein content by 42% and insulin-induced tyrosine phosphorylation of insulin receptor substrate-1 by 28%. Dexamethasone 13-26 insulin Homo sapiens 42-49 9541032-9 1998 Furthermore, dexamethasone down-regulated insulin receptor substrate-1 protein content by 42% and insulin-induced tyrosine phosphorylation of insulin receptor substrate-1 by 28%. Dexamethasone 13-26 insulin Homo sapiens 42-49 9541032-10 1998 The p70 ribosomal S6 kinase was not activated by dexamethasone and instead, dexamethasone attenuated the stimulation of this enzyme activity by insulin. Dexamethasone 76-89 insulin Homo sapiens 144-151 9541032-11 1998 These results suggest that dexamethasone induces the expression of GLUT1 and GLUT4 protein by independent signalling mechanisms with a concomitant depression of intracellular signalling by insulin. Dexamethasone 27-40 insulin Homo sapiens 189-196 9506746-13 1998 Singularly, insulin even inhibited the dexamethasone-induced rise in ob mRNA and leptin release. Dexamethasone 39-52 insulin Homo sapiens 12-19 9468291-11 1998 These results suggest that dexamethasone induces the expression of GLUT1 and GLUT4 protein by independent signalling mechanisms with a concomitant depression of intracellular signalling by insulin. Dexamethasone 27-40 insulin Homo sapiens 189-196 9464884-4 1998 Dexamethasone with insulin increased preadipocyte recruitment two- to fivefold in completely serum-free cultures and in cultures serum-free after seeding and plating in serum for 1 to 3 d. Double staining demonstrated that ECM expression and lipid accretion were tightly coupled and lagged significantly behind preadipocyte recruitment (AD-3 expression). Dexamethasone 0-13 insulin Homo sapiens 19-26 9447952-1 1997 We tested the hypothesis that glucose intolerance develops in genetically prone subjects when exogenous insulin resistance is induced by dexamethasone (dex) and investigated whether the steroid-induced glucose intolerance is due to impairment of beta-cell function alone and/or insulin resistance. Dexamethasone 137-150 insulin Homo sapiens 104-111 9449378-5 1997 Insulin secretion was very fast, and 15 min after induction with dibutyryl cyclic AMP (Bt2cAMP) plus dexamethasone significant amounts of the hormone were released. Dexamethasone 101-114 insulin Homo sapiens 0-7 9447952-1 1997 We tested the hypothesis that glucose intolerance develops in genetically prone subjects when exogenous insulin resistance is induced by dexamethasone (dex) and investigated whether the steroid-induced glucose intolerance is due to impairment of beta-cell function alone and/or insulin resistance. Dexamethasone 137-140 insulin Homo sapiens 104-111 9447952-9 1997 In conclusion, exogenous induced insulin resistance by dex will induce impaired or diabetic glucose tolerance in those genetic relatives of NIDDM patients who have impaired beta-cell function (retrospectively) prior to dex exposure. Dexamethasone 55-58 insulin Homo sapiens 33-40 9447952-9 1997 In conclusion, exogenous induced insulin resistance by dex will induce impaired or diabetic glucose tolerance in those genetic relatives of NIDDM patients who have impaired beta-cell function (retrospectively) prior to dex exposure. Dexamethasone 219-222 insulin Homo sapiens 33-40 9447952-10 1997 These subjects are therefore unable to enhance their beta-cell response in order to match the dex-induced insulin resistant state. Dexamethasone 94-97 insulin Homo sapiens 106-113 9141563-3 1997 Dexamethasone also significantly increased serum leptin (+ 80%) and insulin concentration (+ 83%) but did not affect serum glucose. Dexamethasone 0-13 insulin Homo sapiens 68-75 9395313-10 1997 Finally, insulin inhibition of dexamethasone-induced gene transcription is shown to be conferred by TyrAT 5" sequences. Dexamethasone 31-44 insulin Homo sapiens 9-16 9329344-6 1997 After dexamethasone treatment, significant interactions were observed between the change in plasma leptin and BMI (P = 0.0001), baseline plasma leptin (P = 0.0006) and plasma dexamethasone levels (P = 0.04), but not age (P = 0.28); an apparent interaction with plasma insulin no longer was significant after controlling for BMI. Dexamethasone 6-19 insulin Homo sapiens 268-275 9136082-0 1997 Dexamethasone stimulates leptin release from human adipocytes: unexpected inhibition by insulin. Dexamethasone 0-13 insulin Homo sapiens 88-95 9136082-5 1997 Co-incubation of cells with dexamethasone (10(-7) M) and insulin (10(-7) or 10(-9) M) completely blocked the dexamethasone-stimulated increase in ob mRNA and leptin release. Dexamethasone 109-122 insulin Homo sapiens 57-64 9010325-1 1996 In the present report, the effects exerted by dexamethasone on transepithelial, electrogenic Na+ transport across A6 cell monolayers grown on permeable support were further characterized in terms of time course and relationship to the rate of Na+ transport; furthermore this agonist was compared to vasopressin and insulin. Dexamethasone 46-59 insulin Homo sapiens 315-322 8954054-3 1996 Dexamethasone increased fasting leptin levels by 114 +/- 14% (18.4 +/- 3.3 vs. 39.4 +/- 7.3 ng/ml; P = 0.001) and increased fasting insulin by 51 +/- 12% (P = 0.004). Dexamethasone 0-13 insulin Homo sapiens 132-139 9061710-1 1997 Glucocorticoids or the glucocorticoid analog dexamethasone (DEX) enhances the differentiation of preadipocytes in the presence of insulin and influences preadipocyte proliferation. Dexamethasone 45-58 insulin Homo sapiens 130-137 9061710-1 1997 Glucocorticoids or the glucocorticoid analog dexamethasone (DEX) enhances the differentiation of preadipocytes in the presence of insulin and influences preadipocyte proliferation. Dexamethasone 60-63 insulin Homo sapiens 130-137 9061710-5 1997 However, many more fat cells were induced (258 +/- 15/unit area) when DEX was added with fetal bovine serum (FBS) followed with insulin treatment, compared to DEX with insulin (21.3 +/- 5.1/ unit area) after removal of preadipocytes. Dexamethasone 70-73 insulin Homo sapiens 128-135 8908396-7 1996 CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. Dexamethasone 272-285 insulin Homo sapiens 122-129 8656080-6 1995 Insulin inhibited the promoter activity through sequences located between -344 and -222, and abolished the stimulation by dexamethasone. Dexamethasone 122-135 insulin Homo sapiens 0-7 8842473-9 1996 Furthermore, increased insulin sensitivity and attenuated glucagon responsiveness was also associated with DXM-induced hypocorticalism. Dexamethasone 107-110 insulin Homo sapiens 23-30 8609836-2 1996 It is further assumed that dexamethasone administration in humans causes insulin hypersecretion, although inferences on beta-cell activity have been made in absolute terms and mostly from observations of systemic insulin concentration. Dexamethasone 27-40 insulin Homo sapiens 73-80 8609836-15 1996 In conclusion, after dexamethasone administration, peripheral hyperinsulinemia due to marked prehepatic beta-cell insulin hypersecretion is partially ameliorated by a concomitant increase of hepatic insulin clearance, which is more evident during a FSIGT. Dexamethasone 21-34 insulin Homo sapiens 67-74 8889233-4 1996 When fibroblasts transfected with pBCMGS-neo-Ins-invMMTV were cultured with 1 x 10(-5) M dexamethasone, two of nine clones showed a 10-20% reduction in proinsulin production. Dexamethasone 89-102 insulin Homo sapiens 152-162 8889233-5 1996 On the other hand, all clones of the cells transfected with a control vector containing human insulin cDNA (pBCMGS-neo-Ins) showed an 20-80% increase of proinsulin production when cultured with dexamethazone because of the increase of protein synthesis by glucocorticoids. Dexamethasone 194-207 insulin Homo sapiens 94-101 8889233-5 1996 On the other hand, all clones of the cells transfected with a control vector containing human insulin cDNA (pBCMGS-neo-Ins) showed an 20-80% increase of proinsulin production when cultured with dexamethazone because of the increase of protein synthesis by glucocorticoids. Dexamethasone 194-207 insulin Homo sapiens 153-163 8894479-5 1996 Hence, dexamethasone treatment for 60 h induced insulin resistance but did not enhance insulin responses to glucose or to arginine. Dexamethasone 7-20 insulin Homo sapiens 48-55 8612793-4 1996 Insulin and dibutyryl cyclic AMP both significantly decreased activity in the presence of dexamethasone. Dexamethasone 90-103 insulin Homo sapiens 0-7 7962275-0 1994 Mechanisms of dexamethasone-induced insulin resistance in healthy humans. Dexamethasone 14-27 insulin Homo sapiens 36-43 7488024-1 1995 In this study, we analyzed the role of the TATA box in the regulation of the phosphoenolpyruvate carboxykinase (PEPCK) gene expression by dexamethasone (DEX), retinoic acid (RA), glucagon (via cAMP) and insulin (INS). Dexamethasone 153-156 insulin Homo sapiens 203-210 7544807-3 1995 The effect of dexamethasone is not mediated by changes in IGF-binding proteins, as evidenced by similar effects of dexamethasone on the actions of insulin, PDGF-BB, and the IGF-I analogue long R3IGF-I. Dexamethasone 115-128 insulin Homo sapiens 147-154 7775603-8 1995 In addition to its synergism with IGF-I, preincubation with dexamethasone augmented insulin and epidermal growth factor (EGF) stimulation of [3H]thymidine incorporation; dexamethasone had no effect on platelet-derived growth factor or fibroblast growth factor action. Dexamethasone 60-73 insulin Homo sapiens 84-91 7983014-4 1994 Deletion and site-directed mutations of the hIGFBP-1 promoter (a) identified two glucocorticoid response elements, located within the first 200 bp of the promoter, which are essential for dexamethasone-stimulated promoter activity and which specifically bind human glucocorticoid receptor; (b) showed that a recently characterized insulin-responsive element, located approximately 110 bp 5" to the transcription start site (Suwanichkul, A., Morris, S.L., and Powell, D. R. (1993) J. Biol. Dexamethasone 188-201 insulin Homo sapiens 331-338 7843724-7 1995 Insulin strongly reduced the rise in cholesterol 7 alpha-hydroxylase activity induced by incubation with dexamethasone. Dexamethasone 105-118 insulin Homo sapiens 0-7 7962275-2 1994 The mechanisms responsible for dexamethasone-induced insulin resistance were investigated in healthy human subjects. Dexamethasone 31-44 insulin Homo sapiens 53-60 7523864-0 1994 Identification of cis-elements mediating the stimulation of rat insulin-like growth factor-binding protein-1 promoter activity by dexamethasone, cyclic adenosine 3",5"-monophosphate, and phorbol esters, and inhibition by insulin. Dexamethasone 130-143 insulin Homo sapiens 64-71 7712917-1 1994 It is shown that the maximum specific binding rate (B/T) of erythrocyte membrane receptor to insulin was significantly decreased, the concentration of plasma insulin was significantly increased and the level of plasma glucose was not obviously changed after taking hydrocortisone (1.25mg/kg) or dexamethasone (37.5 micrograms/kg) orally. Dexamethasone 295-308 insulin Homo sapiens 93-100 8027242-4 1994 Postabsorptively, dexamethasone produced mild hyperglycemia (P < 0.003) and a 3-fold rise in plasma insulin (P < 0.001), but no change in forearm phenylalanine balance or kinetics. Dexamethasone 18-31 insulin Homo sapiens 103-110 7523864-13 1994 Insulin inhibition of dexamethasone-stimulated promoter activity was lost after deletion of nt -135 to -92 or mutation of the region between nt -108 and -99. Dexamethasone 22-35 insulin Homo sapiens 0-7 8269993-4 1994 Dexamethasone repressed the G6PD mRNA expression induced by glucose and insulin and decreased this expression when induced by T3, regardless of the presence of insulin. Dexamethasone 0-13 insulin Homo sapiens 72-79 8238089-5 1993 With dexamethasone alone, DHEAS, testosterone, and their ratio were reduced with a concomitant increase (30%) in oral glucose tolerance test insulin levels and a decrease (33%) in erythrocyte insulin binding. Dexamethasone 5-18 insulin Homo sapiens 141-148 8238089-5 1993 With dexamethasone alone, DHEAS, testosterone, and their ratio were reduced with a concomitant increase (30%) in oral glucose tolerance test insulin levels and a decrease (33%) in erythrocyte insulin binding. Dexamethasone 5-18 insulin Homo sapiens 192-199 8238089-6 1993 With DHEA + dexamethasone, the ratio of DHEAS/testosterone increased 16-fold along with a marked improvement in insulin sensitivity, as determined by a more than 30% reduction in fasting and oral glucose tolerance test insulin levels, a threefold stimulation of the rate of glucose disappearance with intravenous insulin, and a 30% increase in insulin binding. Dexamethasone 12-25 insulin Homo sapiens 112-119 8238089-6 1993 With DHEA + dexamethasone, the ratio of DHEAS/testosterone increased 16-fold along with a marked improvement in insulin sensitivity, as determined by a more than 30% reduction in fasting and oral glucose tolerance test insulin levels, a threefold stimulation of the rate of glucose disappearance with intravenous insulin, and a 30% increase in insulin binding. Dexamethasone 12-25 insulin Homo sapiens 219-226 8238089-6 1993 With DHEA + dexamethasone, the ratio of DHEAS/testosterone increased 16-fold along with a marked improvement in insulin sensitivity, as determined by a more than 30% reduction in fasting and oral glucose tolerance test insulin levels, a threefold stimulation of the rate of glucose disappearance with intravenous insulin, and a 30% increase in insulin binding. Dexamethasone 12-25 insulin Homo sapiens 219-226 8238089-6 1993 With DHEA + dexamethasone, the ratio of DHEAS/testosterone increased 16-fold along with a marked improvement in insulin sensitivity, as determined by a more than 30% reduction in fasting and oral glucose tolerance test insulin levels, a threefold stimulation of the rate of glucose disappearance with intravenous insulin, and a 30% increase in insulin binding. Dexamethasone 12-25 insulin Homo sapiens 219-226 8408055-0 1993 Effect of dexamethasone on the alternative splicing of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells. Dexamethasone 10-23 insulin Homo sapiens 59-66 8408055-1 1993 We have shown that culturing HepG2 cells in Ham"s F-12 medium supplemented with calf serum, dexamethasone, and triiodothyronine causes an increase in the insulin sensitivity and responsiveness for glucose incorporation into glycogen. Dexamethasone 92-105 insulin Homo sapiens 154-161 8408055-4 1993 Dexamethasone alone could cause both a switch in expression from the A to the B isoform of the insulin receptor and also an increase in insulin sensitivity for both glucose incorporation into glycogen and 2-deoxyglucose transport. Dexamethasone 0-13 insulin Homo sapiens 95-102 7683515-4 1993 The stimulatory effect of dexamethasone and cAMP, conferred to the IGFBP-1 promoter between 357 and 103 base pairs 5" to the mRNA cap site, is inhibited by insulin. Dexamethasone 26-39 insulin Homo sapiens 156-163 8468366-7 1993 Insulin and T3 produced a high accumulation of malic enzyme mRNA in lactate-pyruvate medium, this effect being decreased by dexamethasone. Dexamethasone 124-137 insulin Homo sapiens 0-7 8471668-4 1993 Specifically, we show that: 1) treatment with a combination of indomethacin and dexamethasone causes the maximum percentage differentiation in the population, 2) addition of indomethacin in combination with either dexamethasone or insulin increases the rate of differentiation, and 3) indomethacin selectively increases the maturation of adipocytes, measured as an increase in the amount of lipid per cell. Dexamethasone 80-93 insulin Homo sapiens 231-238 8276130-4 1993 Induction of MD-IGF-1 cells with dexamethasone (DEX) alone triggered a 29.5-fold increase in secretion of recombinant IGF-1 (348.9 vs 11.8 pg/micrograms DNA), and stimulated a 1.7-fold increase in total DNA within 72 h. Growth of MD-IGF-1 cells was enhanced by exogenous IGF-1, insulin, and TGF-alpha. Dexamethasone 33-46 insulin Homo sapiens 278-285 8276130-4 1993 Induction of MD-IGF-1 cells with dexamethasone (DEX) alone triggered a 29.5-fold increase in secretion of recombinant IGF-1 (348.9 vs 11.8 pg/micrograms DNA), and stimulated a 1.7-fold increase in total DNA within 72 h. Growth of MD-IGF-1 cells was enhanced by exogenous IGF-1, insulin, and TGF-alpha. Dexamethasone 48-51 insulin Homo sapiens 278-285 8339402-0 1993 Suppression of insulin-induced sympathetic activation and vasodilation by dexamethasone in humans. Dexamethasone 74-87 insulin Homo sapiens 15-22 8339402-7 1993 CONCLUSIONS: These results demonstrate a dramatic impairment of insulin-induced sympathetic activation and vasodilation by dexamethasone in lean, healthy humans. Dexamethasone 123-136 insulin Homo sapiens 64-71 8339402-8 1993 This study suggests that dexamethasone administration to lean subjects may offer an experimental model to examine underlying mechanisms that regulate the interplay between cardiovascular, sympathetic, and metabolic effects of insulin. Dexamethasone 25-38 insulin Homo sapiens 226-233 1451738-1 1992 The effects of dexamethasone on the modulation of insulin secretion by recombinant human interleukin-1 beta (IL-1) were examined in HIT-T 15 cells. Dexamethasone 15-28 insulin Homo sapiens 50-57 1451738-0 1992 Dexamethasone attenuates altered insulin secretion elicited by interleukin-1 beta in HIT cells. Dexamethasone 0-13 insulin Homo sapiens 33-40 8436259-0 1993 Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Dexamethasone 10-23 insulin Homo sapiens 27-34 8436259-2 1993 Following dexamethasone treatment the insulin sensitivity index decreased significantly from 6.5 +/- 1.3 to 4.1 +/- 1.0 (microU.ml-1).min-1, p < 0.05. Dexamethasone 10-23 insulin Homo sapiens 38-45 8436259-3 1993 The area under the curve representing above-basal levels of insulin during oral glucose tolerance test increased significantly following dexamethasone treatment from 48132 +/- 9736 to 82230 +/- 14846 pmol.l-1 x 3 h-1, p < 0.05, the area under the curve of islet amyloid polypeptide increased from 1308 +/- 183 to 2448 +/- 501 pmol.l-1 x 3 h-1, p < 0.05. Dexamethasone 137-150 insulin Homo sapiens 60-67 8436259-5 1993 During the oral glucose tolerance test the insulin/islet amyloid polypeptide ratio increased significantly from baseline to 30 min (p < 0.05), then declined towards initial values before and after dexamethasone treatment. Dexamethasone 200-213 insulin Homo sapiens 43-50 1451738-3 1992 In the second experiment, the addition of 10(-7) M dexamethasone prevented the inhibitory effects of IL-1 on insulin secretion. Dexamethasone 51-64 insulin Homo sapiens 109-116 1451738-4 1992 In the third experiment, dexamethasone at 10(-7) M attenuated both the short-term stimulation of insulin release and the long-term suppression of insulin release caused by IL-1. Dexamethasone 25-38 insulin Homo sapiens 97-104 1451738-4 1992 In the third experiment, dexamethasone at 10(-7) M attenuated both the short-term stimulation of insulin release and the long-term suppression of insulin release caused by IL-1. Dexamethasone 25-38 insulin Homo sapiens 146-153 1631088-12 1992 The evaluation of insulin response after Dex may thus allow differentiation of the subset of LIR that run an increased risk of non-insulin-dependent diabetes mellitus. Dexamethasone 41-44 insulin Homo sapiens 18-25 1631088-7 1992 Hyperglycemic clamp revealed that Dex induced a significant increase (P less than 0.05) in insulin response only in HIR. Dexamethasone 34-37 insulin Homo sapiens 91-98 1520733-0 1992 Modulation by dexamethasone of insulin binding and insulin receptor mRNA levels in U-937 human promonocytic cells. Dexamethasone 14-27 insulin Homo sapiens 31-38 1631088-8 1992 Dex effects on insulin release during hyperglycemic clamp were negatively correlated with the glucose area during Dex OGTT (P less than 0.01). Dexamethasone 0-3 insulin Homo sapiens 15-22 1520733-1 1992 Treatment with 5 x 10(-6) M dexamethasone stimulated insulin binding in human promonocytic U-937 cells. Dexamethasone 28-41 insulin Homo sapiens 53-60 1328351-0 1992 Inhibitory effect of dexamethasone on the oxytocin response to insulin-induced hypoglycemia in normal men. Dexamethasone 21-34 insulin Homo sapiens 63-70 1590379-6 1992 Pulse-chase studies showed that the rate of LPL degradation was markedly slowed in the presence of dexamethasone plus insulin compared with insulin alone. Dexamethasone 99-112 insulin Homo sapiens 140-147 1374400-0 1992 Regulation of the expression of pp160, a putative insulin receptor signal protein, by insulin, dexamethasone, and 1-methyl-3-isobutylxanthine in 3T3-L1 adipocytes. Dexamethasone 95-108 insulin Homo sapiens 50-57 1516765-3 1992 Before dexamethasone treatment the incremental insulin level during 0-10 min of arginine was higher in subjects with high (36.5 +/- 6.8 microU/ml) than in subjects with low response (14.5 +/- 2.3 microU/ml), p less than 0.01 for difference. Dexamethasone 7-20 insulin Homo sapiens 47-54 1516765-4 1992 Dexamethasone treatment (6 mg/day for 60 h) markedly enhanced the insulin response to arginine in subjects with high response (+99% 0-30 min) but failed to affect the subjects with low response (+4% 0-30 min). Dexamethasone 0-13 insulin Homo sapiens 66-73 1516765-6 1992 Decreased responsiveness to arginine in subjects with low insulin response, especially during dexamethasone treatment, suggests a Beta-cell capacity defect although a decreased potentiating-sensing effect of glucose cannot be completely ruled out. Dexamethasone 94-107 insulin Homo sapiens 58-65 1372389-7 1992 However, the effect of insulin on C/EBP beta was unexpected and paradoxical: while insulin completely inhibited the transcriptional activation of the C/EBP beta gene in cytokine- and dexamethasone-treated cells, the level of cytoplasmic C/EBP beta RNA was elevated. Dexamethasone 183-196 insulin Homo sapiens 83-90 1372389-8 1992 Quantitation of C/EBP beta mRNA by Northern (RNA) blot analysis and of C/EBP beta DNA binding activity by Southwestern (DNA-protein) blot analysis showed that insulin, when combined with cytokines and dexamethasone, stimulated both the mRNA and DNA binding activity by a factor of 1.6 compared with that of cells treated with cytokines and dexamethasone alone. Dexamethasone 340-353 insulin Homo sapiens 159-166 1714534-4 1991 Dexamethasone induced an increase in basal concentrations of insulin, while IGFBP-1 levels decreased to 18.8 +/- 2 micrograms/L in LIR (P less than .01) and to 14.0 +/- 0.9 micrograms/L in HIR (P less than .05). Dexamethasone 0-13 insulin Homo sapiens 61-68 1590379-5 1992 Dexamethasone added in the presence of insulin increased heparin-releasable and total LPL activity approximately 8-fold but did not alter rates of LPL synthesis compared with insulin alone. Dexamethasone 0-13 insulin Homo sapiens 39-46 1796314-1 1991 The regulatory effect of insulin on the specific binding power of glucocorticoid receptor (GR) of human leukocytes was assessed by the unoccupied receptor sites capable of combining with [3H] labelled dexamethasone measured at 3 and 24 h after incubation with various concentrations of insulin added to the medium. Dexamethasone 201-214 insulin Homo sapiens 25-32 1502874-3 1992 Low levels (1-10 nM) of DEX with insulin doubled (p less than 0.05) specific activity of glycerol phosphate dehydrogenase (GPDH) and doubled (p less than 0.05) the number of detectable fat cells relative to insulin alone. Dexamethasone 24-27 insulin Homo sapiens 33-40 1502874-3 1992 Low levels (1-10 nM) of DEX with insulin doubled (p less than 0.05) specific activity of glycerol phosphate dehydrogenase (GPDH) and doubled (p less than 0.05) the number of detectable fat cells relative to insulin alone. Dexamethasone 24-27 insulin Homo sapiens 207-214 1502874-4 1992 DEX with insulin enhanced the morphological differentiation of preadipocytes and markedly increased fat cell cluster numbers in the presence of hGH. Dexamethasone 0-3 insulin Homo sapiens 9-16 1724187-4 1991 The results also show a complex interaction between insulin, interleukin 6, and glucocorticoids because insulin is able to inhibit the dexamethasone induction of alpha 1-antichymotrypsin, and in the presence of interleukin 6, dexamethasone is able to regulate the production of fibrinogen and prealbumin. Dexamethasone 135-148 insulin Homo sapiens 52-59 1724187-4 1991 The results also show a complex interaction between insulin, interleukin 6, and glucocorticoids because insulin is able to inhibit the dexamethasone induction of alpha 1-antichymotrypsin, and in the presence of interleukin 6, dexamethasone is able to regulate the production of fibrinogen and prealbumin. Dexamethasone 135-148 insulin Homo sapiens 104-111 1724187-4 1991 The results also show a complex interaction between insulin, interleukin 6, and glucocorticoids because insulin is able to inhibit the dexamethasone induction of alpha 1-antichymotrypsin, and in the presence of interleukin 6, dexamethasone is able to regulate the production of fibrinogen and prealbumin. Dexamethasone 226-239 insulin Homo sapiens 52-59 1724187-4 1991 The results also show a complex interaction between insulin, interleukin 6, and glucocorticoids because insulin is able to inhibit the dexamethasone induction of alpha 1-antichymotrypsin, and in the presence of interleukin 6, dexamethasone is able to regulate the production of fibrinogen and prealbumin. Dexamethasone 226-239 insulin Homo sapiens 104-111 1769008-7 1991 Exposure of fibroblasts to 5 x 10(-8) M dexamethasone for 24h increased their responsiveness to insulin but did not influence the response of MCF-7 or HCT-8 cells, whereas insulin-stimulated incorporation of thymidine in T-47D cells was inhibited. Dexamethasone 40-53 insulin Homo sapiens 96-103 1769008-9 1991 These changes may contribute to the well-described stimulatory effects of insulin on tumor cell growth and inhibition of this response with dexamethasone may be relevant to cancer treatment programs. Dexamethasone 140-153 insulin Homo sapiens 74-81 1714534-7 1991 Dexamethasone, which increased the insulin resistance, did not change the relationship between basal IGFBP-1 and the glucose-induced insulin release. Dexamethasone 0-13 insulin Homo sapiens 35-42 1671798-7 1991 In contrast, both insulin (100 pg/ml-10 ng/ml) and insulin-like growth factor-1 (1-100 ng/ml) had no effect on cAMP-stimulated aromatase but potentiated the action of dexamethasone (100 nM). Dexamethasone 167-180 insulin Homo sapiens 18-25 1671798-7 1991 In contrast, both insulin (100 pg/ml-10 ng/ml) and insulin-like growth factor-1 (1-100 ng/ml) had no effect on cAMP-stimulated aromatase but potentiated the action of dexamethasone (100 nM). Dexamethasone 167-180 insulin Homo sapiens 51-58 1703443-1 1991 Following the differentiation of 3T3-L1 fibroblasts by insulin/dexamethasone/methylisobutylxanthine, marked increases in cAMP levels by isoproterenol but not forskolin and in 2-deoxyglucose uptake by insulin occurred. Dexamethasone 63-76 insulin Homo sapiens 55-62 1703443-1 1991 Following the differentiation of 3T3-L1 fibroblasts by insulin/dexamethasone/methylisobutylxanthine, marked increases in cAMP levels by isoproterenol but not forskolin and in 2-deoxyglucose uptake by insulin occurred. Dexamethasone 63-76 insulin Homo sapiens 200-207 1703443-3 1991 On the other hand, insulin/dexamethasone/methylisobutylxanthine caused induction of c-fos proto-oncogene in confluent 3T3-L1 fibroblasts. Dexamethasone 27-40 insulin Homo sapiens 19-26 1965238-6 1990 However, insulin (100 to 1,000 microU/ml) and IGF-I (500 ng/ml) markedly attenuated the stimulatory effect of (Bu)2cAMP, but significantly augmented the dexamethasone-stimulated aromatase activity. Dexamethasone 153-166 insulin Homo sapiens 9-16 1920277-6 1991 In contrast, the surface expression of both insulin and IGF-II binding sites (classical and atypical insulin receptors) increased 1.3 to 1.7-fold after treatment with dexamethasone (200 nM) and decreased 30 to 45% after monensin (1 microM). Dexamethasone 167-180 insulin Homo sapiens 44-51 1920277-6 1991 In contrast, the surface expression of both insulin and IGF-II binding sites (classical and atypical insulin receptors) increased 1.3 to 1.7-fold after treatment with dexamethasone (200 nM) and decreased 30 to 45% after monensin (1 microM). Dexamethasone 167-180 insulin Homo sapiens 101-108 2241906-3 1990 Higher concentrations of insulin (500-1000 mu-units/ml) stimulated protein synthesis in the presence of mepacrine or dexamethasone, suggesting that an alternative pathway may become important in insulin action when phospholipase A2 is inhibited. Dexamethasone 117-130 insulin Homo sapiens 25-32 2175139-0 1990 Inhibition by dexamethasone of arginine vasopressin and ACTH responses to insulin-induced hypoglycemia and cigarette smoking in normal men. Dexamethasone 14-27 insulin Homo sapiens 74-81 2240201-4 1990 DEX significantly increased plasma glucose, insulin, C peptide, and HTGO, while HGP was unchanged. Dexamethasone 0-3 insulin Homo sapiens 44-51 2241906-2 1990 Pre-treatment with the phospholipase A2 inhibitors mepacrine or dexamethasone prevented this stimulation and decreased the release of prostaglandin F2 alpha, implicating the action of phospholipase A2 and the subsequent metabolism of arachidonic acid to prostaglandins in the stimulation of protein synthesis by physiological doses of insulin. Dexamethasone 64-77 insulin Homo sapiens 335-342 2184899-6 1990 The baseline disposal of L-TRP was related neither to insulin nor to FFA concentrations Dexamethasone administration significantly reduced the L-TRP and L-TRP/CAA values and increased FFA and insulin levels. Dexamethasone 88-101 insulin Homo sapiens 192-199 1703443-6 1991 In addition, accumulation of c-fos mRNA by insulin/dexamethasone/methylisobutylxanthine was enhanced in protein kinase C-depleted cells pretreated with phorbol 12-myristate 13-acetate, indicating that protein kinase C may negatively regulate c-fos expression induced by insulin/dexamethasone/methylisobutylxanthine. Dexamethasone 51-64 insulin Homo sapiens 270-277 1703443-6 1991 In addition, accumulation of c-fos mRNA by insulin/dexamethasone/methylisobutylxanthine was enhanced in protein kinase C-depleted cells pretreated with phorbol 12-myristate 13-acetate, indicating that protein kinase C may negatively regulate c-fos expression induced by insulin/dexamethasone/methylisobutylxanthine. Dexamethasone 278-291 insulin Homo sapiens 43-50 35603580-8 2022 Dexamethasone treated islet grafts revealed a good functional response to high glucose stimulation despite there was a transient suppression of insulin secretion from week 8 to 12. Dexamethasone 0-13 insulin Homo sapiens 144-151 2407926-0 1990 Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Dexamethasone 11-24 insulin Homo sapiens 44-51 2407926-0 1990 Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Dexamethasone 11-24 insulin Homo sapiens 56-66 2407926-0 1990 Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Dexamethasone 11-24 insulin Homo sapiens 59-66 2407926-1 1990 We compared the effects of dexamethasone-induced insulin resistance on B-cell secretory performance in 12 low insulin responders (LIR) and in eight high insulin responders (HIR). Dexamethasone 27-40 insulin Homo sapiens 49-56 2407926-4 1990 Dexamethasone treatment increased fasting levels of total immunoreactive insulin (IRI), C-peptide, and proinsulin, as well as the proinsulin to IRI ratio to a similar degree in LIR and HIR. Dexamethasone 0-13 insulin Homo sapiens 73-80 2407926-4 1990 Dexamethasone treatment increased fasting levels of total immunoreactive insulin (IRI), C-peptide, and proinsulin, as well as the proinsulin to IRI ratio to a similar degree in LIR and HIR. Dexamethasone 0-13 insulin Homo sapiens 103-113 2407926-4 1990 Dexamethasone treatment increased fasting levels of total immunoreactive insulin (IRI), C-peptide, and proinsulin, as well as the proinsulin to IRI ratio to a similar degree in LIR and HIR. Dexamethasone 0-13 insulin Homo sapiens 130-140 2407926-9 1990 The effects of dexamethasone on insulin secretion varied among individuals, since steroid treatment failed to affect IRI responses to glucose in two LIR and two HIR. Dexamethasone 15-28 insulin Homo sapiens 32-39 1710557-6 1990 Dexamethasone inhibited the effects of 100 microU insulin/ml in the presence of serum and induced insulin resistance; in the presence of 25 or 100 nM dexamethasone insulin was ineffective at concentrations below 250 microU and 1 mU/ml respectively. Dexamethasone 0-13 insulin Homo sapiens 50-57 1710557-6 1990 Dexamethasone inhibited the effects of 100 microU insulin/ml in the presence of serum and induced insulin resistance; in the presence of 25 or 100 nM dexamethasone insulin was ineffective at concentrations below 250 microU and 1 mU/ml respectively. Dexamethasone 0-13 insulin Homo sapiens 98-105 1710557-6 1990 Dexamethasone inhibited the effects of 100 microU insulin/ml in the presence of serum and induced insulin resistance; in the presence of 25 or 100 nM dexamethasone insulin was ineffective at concentrations below 250 microU and 1 mU/ml respectively. Dexamethasone 0-13 insulin Homo sapiens 98-105 34603025-8 2021 In vitro, gastrodin alleviated insulin resistance by increasing glucose consumption, glucose uptake, and glycogen content in dexamethasone-induced HepG2 cells. Dexamethasone 125-138 insulin Homo sapiens 31-38